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Abstract

In our previous work we demonstrated that the integrin antagonist, HYD1,
induced necrotic cell death in myeloma cell lines in vitro and in vivo as a single agent. In
order to further delineate biomarkers of response to HYD1 we developed an isogenic
drug resistant variant named H929-60. We show that the acquisition of resistance
towards HYD1 correlates with reduced expression of the cleaved α4 integrin subunit and
beta 1 integrin. Moreover, we demonstrate that HYD1 interacts with α4 integrin in
myeloma cells. Consistent with reduced VLA-4 expression, the resistant variant showed
ablated functional binding to fibronectin, VCAM-1 and the bone marrow stroma cell line,
HS-5. The reduction in binding to extracellular matrices of the resistant variant
translated to sensitivity to melphalan and bortezomib induced cell death in the bone
marrow stroma co-culture model of drug resistance. Moreover, CD138 positive myeloma
cells were more sensitive to HYD1 induced cell death compared to the CD138 negative
fraction, and potency of HYD1 induced cell death significantly correlated with α4
integrin expression. We were also able to show that reducing α4 or β1 integrin using
shRNA strategies was sufficient to cause resistance in myeloma cell lines. In addition we
investigated the effects of cyclized variants of HYD1 to improve potency of the agent.
One such compound, named HM-27, was determined to be 30 fold more active in H929
cells when compared to HYD1. HM-27 and HYD1 were determined to have similar

xiii

mechanisms of action as H929-60 cells were shown to be resistant to both compounds
when compared to H929 cells. We further characterized HM-27’s mechanism of action
by investigating what effects HM-27 induced Ca2+ oscillations had on HM-27 induced
cell death. The increases in intracellular Ca2+ seen after treatment with HM-27 were
determined to occur via release from ER stores and not through influx through plasma
membrane channels. Inhibiting Ca2+ release from the ER also potentiated the effects of
HM-27 in MM cells. Furthermore, inhibiting Ca2+ release from the ER was also shown to
block the onset of autophagy after ER treatment. Treating cells with the lysosomotropic
agent, chloroquine, was shown to potentiate the activity of HM-27 in vitro and ex vivo.
HM-27 was also shown to have activity in an in vivo model with combination treatment
containing bortezomib and HM-27 increasing mouse survival. Collectively our data
indicate that VLA-4 expression is a critical determinant of response to HYD1 induced
cell death. We also showed that increases in intracellular Ca2+ seen after treatment with
HM-27 had a cytoprotective effect in MM cells. Moreover, neutralizing autophagy
potentiates HM-27 induced cell death in vitro and ex vivo while combining bortezomib
and HM-27 increased survival in vivo. These data continue to provide rationale for
further pre-clinical development of HYD1 as a novel anticancer agent.
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Chapter I: Introduction
Hematopoiesis
Because mature blood cells are predominately short lived, approximately 1 x 1010
red blood cells and 1 x 109 white blood cells are produced per day to maintain normal
levels in the peripheral circulation. This production of new cells is accomplished by the
differentiation of hematopoietic stem cells (HSCs) through the highly regulated process
termed hematopoiesis. In vertebrates, blood stem cells are produced in a variety of sites
that change during development [1]. In mammals, these hematopoiesis sites include the
yolk sac, the aorta-gonad mesonephros (AGM) region, the fetal liver and the bone
marrow. After birth, hematopoiesis ceases in the yolk sac, AGM region and the fetal
liver with the bone marrow becoming the predominant site for the production of new
blood cells.
HSCs are self-renewing hematopoietic cells that reside in the bone marrow of
adult humans. Operationally these cells are defined by their capacity to reconstitute the
entire blood system of a recipient whose bone marrow has been destroyed by irradiation
or treatment with toxic drugs [2]. In addition to their self renewing capacity, HSCs can
also differentiate into multipotential progenitors (MPPs) which in turn can differentiate
into either common myeloid progenitors (CMPs) or early lymphoid progenitors (ELPs)
[3]. CMPs differentiate into megakaryocytes, myeloid cells or erythrocytes while ELPs
differentiate into lymphocytes.
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Cells derived from CMPs have a variety of different functions. Platelets are
produced in the bone marrow via budding off from megakaryocytes and are involved in
hemostasis, leading to the formation of blood clots. Erythrocytes are the most common
type of blood cell and are responsible for delivering oxygen throughout the body.
Myeloid cells can further differentiate into a category of leukocytes that include
granulocytes and monocytes. Granulocytes, also known as polymorphonuclear
leukocytes (PMLs) because of the abnormal shapes of their nuclei, are characterized by
the presence of small particles named granules which reside in the cytoplasm. PMLs
consist of neutrophils, eosinophils and basophils. Neutrophils are the most abundant
granulocyte, constituting 50% of total circulating white blood cells, and aid in the innate
immune response by releasing bacteria-killing enzymes or engulfing invading
microorganisms or particles by phagocytosis. Eosinophils are important mediators of
allergic responses and also play a role in fighting viral and parasitic infections. Basophils
are the least common type of granulocyte and like eosinophils function in the immune
response to allergens and parasites. Monocytes can differentiate into macrophages,
which also act as phagocytes. Monocytes can also differentiate into dendritic cells,
which capture antigens and function as antigen presenting cells (APCs), or cells that
enable the recognition of the antigen by T-cells.
ELPs can differentiate into bursa-derived cells (B cells), thymus cells (T cells) or
natural killer (NK) cells. B cells are an integral part of the adaptive immune response
and function as APCs and also as antibody producing cells. There are several subsets of
T cells which each have a distinct function. T helper cells are activated by APCs and
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Figure 1: The process of hematopoiesis. The cellular components of the blood are all
derived from hematopoietic stem cells. Myelocytes, megakaryocytes and red blood cells
are derived from common myeloid progenitors and function in the innate and adaptive
immune response, blood clotting and carrying oxygenated throughout the body
respectively. Lymphocytes are derived from early lymphoid progenitor cells and
constitute the backbone of the adaptive immune response while plasma cells are
teminally differentiated B cells and are an integral part of the humoral immune response

function in the maturation of B cells and activation of cytotoxic T cells and macrophages.
Cytotoxic T cells are responsible for the destruction of dysfunctional somatic cells and
accomplish this by releasing the cytotoxins perforin, granzyme and granulysin.
Regulatory T cells are imperative for the maintenance of immunological tolerance and
Natural killer T cells which help in the innate immune response by recognizing glycolipid
antigen. Natural Killer cells are a part of the innate immune response and need no
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activation from t helper cells in order to release cytotoxins to destroy tumors and virally
infected cells.
B cell Differentiation
Normal B-cell differentiation begins in the bone marrow. ELPs can differentiate
into either early T-cell-lineage progenitors (ETPs) or into the bone marrow common
lymphoid progenitors (CLP) which can generate B cells, NK cells and T cells [4]. As
CLPs are pluripotent, it is the expression of a specific B cell marker B220 by a subset of
the population, termed pro-B cells, that initiates the B cell differentiation pathway. Pro-B
cells undergo a process known as VDJ recombination where the immunoglobulin heavy
chains (IgH) are assembled from variable(V), diversity(D), and joining(J) gene segments
[5]. The pre-B cell receptor (pre-BCR) formed from the VDJ recombination is then
expressed on the surface of pre-B cells to act as a checkpoint to determine success of
recombination.

If recombination is successful, pre-b cells undergo substantial clonal

proliferation and VJ recombination where the immunoglobulin light chain (IgL) of B cell
receptors (BCR) are formed. In addition to the formation of the BCR IgL, pre-B cells also
require the presence of immunoglobulin M (IgM) on the surface to proceed to negative
selection [6]. Immature B220+IgM+ B cells are subsequently tested for autoreactivity.
Some B cells that are autoreactive can be rescued by a secondary immunoglobulin gene
rearrangement known as receptor editing while others that are autoreactive are eliminated
by anergy [7]. B cells that pass these requirements are known as naïve B cells leave the
bone marrow and circulate in the blood.
Naïve B cells that leave the bone marrow continue their development in the
spleen. In the spleen naïve B cells pass through 2 transitional stages and another round of
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negative selection. While a small percentage of transitional B cells home to the splenic
marginal zone and become naïve marginal zone B cells, the vast majority of naïve B cells
mature into follicular B cells. These follicular B cells circulate between the spleen,
lymph nodes and bone marrow until they expire or encounter antigen and undergo further
development. After antigen uptake and subsequent activation by T cells, B cells migrate
into the center of the primary follicles forming the germinal center [8].
Germinal B cells comprise two distinct areas of the germinal center. In the dark
zone, B cells are termed centroblasts. Centroblasts main function is to proliferate and
undergo hypersomatic mutations of the immunoglobulin variable region resulting in an
alteration of the affinity of the antibody produced by the cell. By this mechanism there is
a marked increase in intraclonal diversity in a population of cells that are derived from a
few precursors. In the light zone, B cells are termed centrocytes. Centrocytes are the
result of hypersomatic mutations of the immunoglobulin variable region and are activated
by selection from T cells or follicular dendritic cells that are also present in the region.
Centrocytes and centroblasts are very sensitive to apoptosis as they switch off expression
of Bcl-2-like protein 1 (Bcl-x) while in the germinal centers. Centrocytes that do not
display increased affinity to antigen undergo apoptosis while centrocytes that do display
increased affinity for antigen turn back on expression of Bcl-x [9]. Surviving centrocytes
differentiate into either long-lived memory B cells which reside in the follicle marginal
zones or long-lived plasma cells which primarily reside in the bone marrow.
Plasma Cells
Plasma cells are recognized as an integral part of the humoral immune response
whose primary function is the production and secretion of antigen specific antibodies.
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During B cell differentiation, two distinct types of plasma cells can be generated; shortlived or long-lived plasma cells. Short-lived plasma cells are generated from follicular B
cells that do not undergo affinity maturation therefore secreting antibodies that possess a
low affinity for antigen. Short-lived plasma cells serve in the early defense of
immunogens during the primary immune response while higher affinity antibodies are
produced in the germinal center. Long-lived plasma cells are generated from germinal
center B cells that do undergo affinity maturation hence secreting antibodies that possess
a high affinity for antigen. While a proportion of plasma cells generated from germinal
center B cells are lost after antigenic challenge, some plasma cells that are able to access
the bone marrow microenvironment niche are able to survive indefinitely [10].
Plasma cells are identified as having different expression of cell surface proteins
than B cells and early plasmablasts. Plasma cells show decreased expression of proteins
important during B cell differentiation like CD19, B220, MHC class II, and surface Igs.
In contrast, there is increased expression of cell surface proteins like the chemokine
receptor type 4 (CXCR4), interleukin-6 (IL-6) receptor, syndecan-1 (CD138) and CD44.
These receptors have been shown to play a role in plasma cell homing and survival in the
bone marrow microenvironment. Newly formed plasma cells have been shown to
express high levels of the chemokine ligand 12 (CXCL12) receptor CXCR4 which
enables plasma cells to migrate to bone marrow stromal cells (BMSCs) [11]. Once in the
bone marrow microenvironment (BME), plasma cells need physical interaction with
stromal cells in order to persist. CD138 has been shown to facilitate plasma cell
adherence to BMSCs through an interaction with type 1 collagen [12]. Plasma cell
interaction with stromal cells has also been shown to induce stromal cell production and
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secretion of IL-6. IL-6 in turn binds to the IL-6 receptor on plasma cells and promotes
plasma cell survival [13]. The interaction of CD44 with a ligand on the stromal cells has
also been shown to induce production of IL-6 [14]. In addition to IL-6 and CXCL12,
cytokines like interleukin-5 (IL-5) and tumor necrosis factor-alpha (TNF-alpha) have also
been shown to mediate plasma cell longevity (Cassese 2003).
In an adult human, the percentage of plasma cells constitutes about 0.1-1 % of
bone marrow (BM) cells [15]. This frequency of plasma cells is stably maintained over
the years even though an individual generates around 10^4-10^5 new plasma cells every
year [16]. With each new infection, there is competitive displacement of some
established plasma cells by newly formed plasma cells in order to maintain the frequency
of plasma cells in the BM and add new specificities to the plasma cell population. It has
been shown that non-specific plasma cells appear in circulation after immunization
indicating that some established plasma cells are removed from the BM
microenvironment after each infection in order to maintain plasma cell numbers [17]
When a plasma cell clone accumulates and disrupts the normal frequency of plasma cells
in the bone marrow, it is characterized as a plasma cell disorder.
Several forms of plasma cell disorders can be distinguished. Plasma cell
leukemia is the least common form of plasma cell neoplasms accounting for 2-3% of
plasma cell disorders. It is one of the most aggressive neoplasms and is diagnosed when
more than 20% of the peripheral blood contains plasma cells. Plasmacytomas are clonal
proliferations of plasma cells that grow in soft tissue (extraosseous) or bone (osseous).
These neoplasms are also rare and account for 5 % of plasma cell disorders. The most
common plasma cell neoplasm is termed multiple myeloma (MM) which is a malignant
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proliferation of a plasma cell clone which is dependent on the bone marrow
microenvironment for survival and proliferation.
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Chapter II: Multiple Myeloma
Characterization of Multiple Myeloma
MM is a neoplastic cell disorder that is characterized by clonal expansion of
malignant plasma cells in the bone marrow microenvironment and increased levels of
secreted paraprotein, which consists of either an immunoglobulin or an IgL, in the blood
or urine [18]. It is the second most common hematologic malignancy, accounting for
13% of hematologic cancers and 1% of all cancers. The median age of diagnosis is
approximately 65, with occurrence in men being more common. The symptoms
associated with MM consist of hypercalcemia, renal insufficiency, anemia, and bone
lesions (CRAB). With the continued discovery of newer and more effective therapies,
the 5 year survival rate of patients diagnosed with MM has increased from 25% to 35%.
There are four stages of progression associated with MM that are categorized into
2 distinct groups, asymptomatic plasma cell dyscrasia and symptomatic plasma cell
dyscrasia. The 2 asymptomatic disorders are multiple myeloma precursor diseases and
are termed monoclonal gammopathy of unknown significance (MGUS) and smoldering
multiple myeloma. MGUS is defined as the presence of serum M-protein < 3 g/dL with
fewer than 10% monoclonal plasma cells in the bone marrow. MGUS is also
characterized by lack of organ damage. MGUS is present in over 3% of the population
over 50 years old with an annual progression risk to MM of 1% [19]. In addition to being
more prevalent in older populations, MGUS is also 2 times higher in African Americans
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compared with Whites [20]. It has also been demonstrated that most cases of MM are
preceded by MGUS. In one study serum samples were collected from 77,000 healthy
donors. Of the 71 patients who developed multiple myeloma at the 10 year follow up, the
presence of MGUS was detected in 100 % of the cases in the years prior to the diagnosis
of MM [21].
Smoldering myeloma is another asymptomatic plasma cell dyscrasia that has been
shown to progress to MM. Smoldering myeloma is defined as the presence of serum
protein > 3 g/dL with greater than 10 % monoclonal plasma cells in the bone marrow
with lack of organ damage. Smoldering myeloma has a much higher risk of progression
to multiple myeloma (10%) than MGUS [22]. Once patients with smoldering myeloma
or MGUS start experiencing symptoms associated with MM they are diagnosed with
either intermedullary myeloma or extramedullary myeloma. Intermedullary myeloma is
defined as MM which can only exist within the confines of the bone marrow
microenvironment while extramedullary myeloma is defined as MM which can exist
outside of the bone marrow microenvironment and is often called primary plasma cell
leukemia.
MM can also be characterized by the presence of genetic aberrations present in
the tumor. Even though cytogenetic analysis can be difficult because of the low
proliferative fraction of MM, techniques like fluorescence in situ hybridization (FISH)
have been used to distinguish tumors with differing cytogenetics. Structural and
numerical chromosomal abnormalities are found in 55-70% in newly diagnosed
symptomatic patients. These abnormalities are usually hyperdiploid with multiple
trisomies or nonhyperdiploid with IgH translocations. In one study using FISH, it was
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shown that 42% of MGUS, 63% of smoldering myeloma and 57% of MM cases were
hyperdiploid [23]. The hyperdiploid karyotype is usually characterized by trisomies of
chromosomes 3,5,7,9,11,15,19 and 21 [24]. While the hyperdiploid group is regarded as
neutral in terms of prognosis, the nonhyperdiploid group is associated with poorer overall
survival.
The nonhyperdiploid classification consists of clones containing hypodiploid,
pseudodiploid and tetraploid variants. The common nonhyperdiploid translocations
t(4;14)(p16;q32) and t(14;16)(q32;q23) are usually associated with poor prognosis while
the t(11;14)(q13;q32) are associated with a favorable prognosis [25]. For the two
translocations with poor prognosis, the immunoglobulin switch region on chromosome
14 is juxtaposed to MAF on chromosome 16 and MMSET on chromosome 4 [26]. These
translocations are usually a result of errors in IgH switch recombination or hypersomatic
hypermutation during B cell differentiation [27]. The incidence of IgH translocations
increases from 50% in MGUS to 80% in human MM cell lines. In addition to primary
IgH translocations, virtually all MM and MGUS patients have cyclin D dysregulation as a
primary event. As disease progresses MM becomes more proliferative and develops a
number of secondary aberrations.
Four main secondary aberrations are most often reported. These include the
deletion of chromosome 13, deletions and amplications in chromosome 1, the deletion of
chromosome 17p13 and translocations of Myc [28]. Chromosome 13 aberrations are
found in 50% of cases and are associated with an unfavorable prognosis [29].
Chromosome 1 aberrations are the most common type of aberration in MM and are also
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FIGURE 2: Key events in the progression of MM. There are four stages of myeloma
categorized into 2 groups, asymptomatic (MGUS and SM) and symptomatic
(intramedullary and extramedullary myeloma) plasma cell dyscrasias. Primary
cytogenetic aberrations result in development of MGUS. Secondary cytogenetic
aberrations result in progression to smoldering myeloma and finally advanced stages of
the disease.

associated with poor prognosis [30]. The deletion of 17p13 leads to the loss of
heterozygosity of the tumor suppressor gene TP53 and is sited as an important molecular
cytogenetic factor and is an indicator of very poor prognosis [31]. Translocations of the
oncogene Myc are involved in up to 45% of patients and are considered a late event in
tumor progression when tumors are less dependent on stromal adhesion [32]. In addition
to these secondary aberrations, the activation of NRAS and KRAS and the inactivation of
cyclin-dependent kinase inhibitors have also been implicated in disease progression [33].
In addition to cytogenetic abnormalities multiple myeloma cells also have
different surface markers compared to normal plasma cells. CD56 is an adhesion
molecule that is expressed in 70-80% of MM cases but is not expressed in normal plasma
12

cells [34]. CD28 is another surface protein that increases expression as cells progress to
MM. In one study, CD28+ plasma cells were detected in 19% of 31 monoclonal
gammopathy of undetermined significance, 41% of 116 MM, and 100% of 13 human
myeloma cell lines [35]. The CD44 variant CD44v9 has also been shown to be
overexpressed on MM cells with expression inducing production of IL-6 by bone marrow
stromal cells. Overexpression of the CD44v9 on MM cell lines has also been shown to
have a poor prognosis.
Current Treatment Options
MM treatment is focused on decreasing the signs and symptoms of the disease.
While asymptomatic myeloma requires only evaluation since treatment shows no added
benefit, symptomatic disease should be treated immediately [36]. 73% of patients
diagnosed with symptomatic myeloma have anemia, which is usually related to myeloma
marrow infiltration [37]. Bone lesions develop in around 80% of patients while renal
dysfunction occurs in 30% of newly diagnosed patients. For patients who meet the
diagnostic criteria for myeloma, including clonal plasma cells >10% on a bone marrow
biopsy and myeloma related organ impairment, the international staging system (ISS) is
used. The ISS defines three risk groups based on serum β2-microglobulin and albumin
levels [38]. Once the diagnostic testing is complete, initial treatment is administered
which is based on a person’s age and prognosis factors.
The treatment strategy for MM is mainly related to patient age. For patients 65 or
younger who do not have substantial organ dysfunction autologous stem cell
transplantation is administered in combination with high dose chemotherapy. The
chemotherapy consists of either thalidomide or lenalidomide-doxorubicin treatment or
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bortezomib induced treatment [39]. Older patients or patients with preexisting conditions
have a hard time withstanding autologous stem cell transplantation. For these patients
either 3 drug therapy or 2 drug therapy has been used. Three drug therapy consists of the
use of melphalan, prednisone and one of lenolidomide, thalidomide or bortezomib. In a
sample study using melphalan, prednisone and bortezomib the proportions of patients
with a partial response or better were 71% in the bortezomib group and 35% in the
control group; complete-response rates were 30% and 4%, respectively [40]. 2 drug
induction consists of the combination of dexamethasone and either thalidomide or
lenalidomide. In a sample study using lenalidomide and dexamethasone 31 of 34 patients
achieved an objective response, including 6% achieving complete response and 32%
achieving near complete response [41]. Sometimes after initial therapy an ongoing
maintenance therapy is administered to prolong progression free survival.
The natural progression of patients with MM is for the occurrence of relapse after
treatment. Patients who have progressive disease are classified as having either relapsed
or refractory myeloma. Relapsed MM is defined where a patient who has achieved
complete response through initial therapy experiences progressive disease, whereas
refractory MM is defined as a scenario where a patient is unresponsive to current therapy
or progresses within 2 months of last treatment [42]. In addition, some patients fail to
achieve a response after induction therapy and then progress are considered patients with
primary refractory myeloma. When these situations arise, new treatment regimens are
administered to prolong survival. Some patients are given conventional chemotherapy
which includes approaches containing high-dose dexamethasone; high-dose melphalan;
and combinations of vincristine, doxorubicin, and dexamethasone (VAD). High-dose
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dexamethasone is used for patients who are not candidates for more aggressive treatments
and has shown response rates ranging from 18-27% with 4 day courses at 40 mg per day
[43]. High-dose melphalan has been used for over 20 years and it was shown in one
study that 61% of patients responded after treatment with 100 mg/m2 with an autologous
bone marrow infusion [44]. VAD is a widely used regimen for refractory myeloma with
an increase in response in relapsed patients compared to dexamethasone treatment alone
[45]. In addition to VAD, doxorubicin and dexamethasone have been combined with
other chemotherapeutic agents including prednisone, carmustine, cyclophospamide and
melphalan to achieve response in relapsed and refractory myeloma patients.
The novel therapeutic agents thalidomide, lenalidomide and bortezomib have also
been used to treat relapsed and refractory patients. Thalidomide alone was shown to
produce partial remission in 30% of relapsed patients with a 1 year survival rate of 60%
[46]. Combination therapy with thalidomide and conventional drugs usually results in an
overall response rate (ORR) of 60%-70% with complete response rates of 10-20% [47].
Lenalidomide has also been shown to have an effect in relapsed patients with a
combination of lenalidomide and dexamethasone having an ORR of 60% compared to an
ORR of 20% for dexamethasone alone [48]. The protease inhibitor bortezomib has also
been shown to be an attractive therapy for targeting relapsed/refractory MM. As a single
agent bortezomib was shown to elicit an ORR of 38% compared to 18% for high-dose
dexamethasone [43]. Bortezomib is also used in combination studies since it has mild
myelosuppression and lack of thrombogenecity seen with thalidomide and lenalidomide.
For example, a recent study with bortezomib combined with prednisone and
cyclophospamide produced an ORR of 85% with 50% of patients exhibiting a complete
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response of over a year [49]. Even though new regimens have been utilized to prolong
intervals of progressive disease and patient survival, MM is currently defined as an
incurable disease, because of the ultimate development of drug resistance.
Drug Resistance in Multiple Myeloma
Because multiple myeloma ultimately develops drug resistance to treatment
strategies, researchers have invested considerable amounts of research into delineating
the mechanisms by which multiple myeloma cells develop resistance. Even after therapy
in which complete response is achieved, small populations of myeloma cells are able to
survive, a condition known as minimal residual disease (MRD). These cells have
historically been able to evade detection as they do not secrete detectable amounts of
serum or urine monoclonal proteins by established diagnostic tests [50]. However,
techniques being developed including the use of a polymerase chain reaction (PCR) with
patient specific primers have been able to detect MRD in patients that have been
classified as having a complete response [51]. Subsequent expansion of these cells
correlates with drug relapse, frequently with an acquired multidrug resistant phenotype
making salvage therapy unsuccessful even with novel therapeutic agents. MRD is
thought to escape drug treatment through two distinct methods of resistance, de novo
resistance and acquired resistance. De novo resistance is defined as resistance that is
present prior to drug selection and selection of drug resistance. Mechanisms associated
with de novo resistance help contribute to the failure to eliminate MRD and contribute to
the emergence of acquired drug resistance.
Soluble factors and direct MM cell contact both contribute to de novo drug
resistance. Soluble factors that contribute to de novo drug resistance include both
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chemokines and cytokines. The chemokine SDF-1 has been shown to be important for
MM homing to the bone marrow via interactions with the CXC chemokine receptors
CXCR4 and CXCR7. SDF-1 has been shown to induce motility and cytoskeletal
rearrangement in MM cells while inhibition of the CXCR4 receptor with AMD3100
reduced motility [52]. Expression of the SDF-1 receptor CXCR7 has also been shown to
increase tumor cell adhesion properties [53]. SDF-1 has also been shown to up-regulate
the production of the cytokine IL-6 by stromal cells, therefore enhancing MM cell
survival [54].
In addition to the chemokine SDF-1, cytokines have also been shown to
contribute to de novo drug resistance in MM cells. The cytokine IL-6 has been identified
as one of the main factors that contributes to the growth and survival of MM cells in the
bone marrow microenvironment. IL-6 binds to IL-6Rα and leads to the dimerization and
phosphorylation of gp130 [55]. Phosphorylation of gp130 leads to the initiation of 3
major signaling pathways in MM cells that contribute to drug resistance: the Ras/RafMEK-ERK pathway; the phosphatidylinositol 3-kinase (PI3K) pathway and the
JAK/STAT pathway. Ras gene mutations have been shown to have an oncogenic effect
and occur in 30% to 40% of patients with MM [56]. In addition to specific mutations,
IL-6 has been shown to also activate Ras by the phosphorylation of Shc through cytokine
stimulation [57]. This activation of Ras by IL-6 has been shown to trigger the ERK
cascade and subsequent growth of MM cells [58]. IL-6 was also shown to activate AKT
in MM cells and subsequently protecting the cells from dexamethasone induced apoptosis
[59]. IL-6 has also been shown to activate the JAK/STAT pathway and in particular upregulate the expression of the anti-apoptotic proteins B-cell lymphoma-extra large (BCL-
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xL) and myeloid cell leukemia sequence 1 (Mcl-1) [60]. Expression of Mcl-1 in
particular has been shown to correlate to an increase in dexamethasone resistance.
In addition to IL-6, other cytokines have been shown to play a role in de novo
drug resistance. TNF-α has been shown to activate NF-κβ and up-regulate IL-6 secretion
which contributes to mm growth and survival [61]. Insulin-like growth factor-1 (IGF-1)
is also an important survival factor in multiple myeloma cells. For example, it has been
shown that IGF-1 mediates the down regulation of the proapoptotic BH3-only protein
Bim and protecting myeloma cells from bortezomib and melphalan induced cell death
[62]. The vascular endothelial growth factor (VEGF) has also been shown to protect
multiple myeloma cells against apoptosis by inducing the up-regulation of Mcl-1 [63].
Interferon-alpha (IFN-alpha) is a cytokine that has been shown to induce autocrine
production of IL-6 in myeloma cell lines and protect myeloma cells from dexamethasone
treatment [64].
Direct cell contact of MM cells to bone marrow stroma cells and extracellular
matrix (ECM) proteins has also been shown to play a prominent role in MM pathogenesis
and MDR. Multiple adhesion molecules have been shown to cause cell adhesion
mediated-drug resistance (CAM-DR), including CD44, lymphocyte-associated function
antigen-1 (LFA-1), Notch-1 and integrins. CD44 has been shown to adhere to
hyaluronan and this engagement promotes dexamethasone resistance in myeloma cells
[65]. LFA-1 binds to the intracellular adhesion molecule 1 (ICAM) and the blockage of
this adhesion with an anti-LFA1 antibody has been shown to reverse CAM-DR to
melphalan in myeloma cells [66]. Inhibition of notch with a gamma secretase inhibitor
was shown to
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Figure 3: de novo resistance in MM. Soluble factors and direct MM cell contact both
contribute to de novo drug resistance. IL-6 leads to the activation of major signaling
pathways leading to increased cell survival and proliferation. Adhesion of MM cells to
BM stroma cells and ECM proteins like FN lead to CAM-DR.

induce apoptosis and increase sensitivity to doxorubicin and melphalan [67]. In addition
to adhesion molecules, it has been shown that genes associated with certain myeloma
translocation gene products, specifically the MMSET gene and the t (4:14) translocation,
are associated with increased myeloma cell adhesion and tumorigenicity [68].
β1 integrin specific CAM-DR was initially described in studies showing that β1
integrin mediated adhesion to fibronectin (FN) conferred resistance to melphalan and
doxorubicin [69]. Adhesion by integrins has been shown to modify distinct cellular
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processes leading to drug resistance. For example, β1 integrin-mediated adhesion to FN
upregulates p27kip1 and induces cell cycle arrest and resistance to the topoisomerase
inhibitor etoposide [70]. MM cell adhesion to FN was also shown to control the
localization of cFLIP, making it able to associate with FADD and block the extracellular
apoptotic cascade [71]. Leukemic cells were also shown to downregulate the expression
of the proapoptotic protein bim resulting in CAM-DR [72]. In addition to β1 integrin
other integrins have been implicated in CAM-DR. Silencing of the β7 integrin reversed
FN induced CAM-DR in myeloma cells to bortezomib and melphalan.
De novo resistance results in the acquisition of mechanisms that confer resistance
to multiple classes of therapeutic agents, also known as acquired drug resistance.
Mechanisms that result in acquired resistance include: reduction in intracellular drug
accumulation; alterations in drug targets; inhibition of apoptosis; and enhanced DNA
repair. An increase in the drug-efflux pump P-glycoprotein has been shown to reduce
intracellular drug accumulation and increase resistance to therapy. Resistance to
melphalan and thalidomide has been associated with reduced drug accumulation in
multiple myeloma cells [73, 74]. Mutations in drug targets have also led to acquired
resistance to therapy. Alterations in topoisomerase II have led to resistance from
etoposide while alterations in the glucocorticoid receptor have led to resistance to
dexamethasone [75]. An alteration in a specific subunit of the proteasome has also led to
bortezomib resistance in MM cells [76]. Upregulation of proteins that inhibit apoptosis
also confers acquired drug resistance. The upregulation of Bcl-2 has also been shown to
confer drug resistance to dexamethasone and doxorubicin [77]. Elevated levels of the
inhibitor of apoptotic protein XIAP has also been shown to correlate with poorer survival
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in patients post chemotherapy [78]. Finally, alterations in DNA-repair pathways have
been shown to contribute to acquired resistance in MM cells. Enhanced DNA repair via
the Fanconi Anemia pathway has been shown to contribute to melphalan resistance in
MM cells [79]. By understanding mechanisms of de novo and acquired resistance, new
therapeutic targets are being identified to reduce MRD or target known markers of
relapsed/refractory patients.
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Chapter 3: Integrins
Structure and Function
Integrins are transmembrane heterodimeric proteins which consist of noncovalently bound alpha and beta subunits. In vertebrates, there are 18 alpha and 8 beta
subunits that can assemble to form 24 distinct receptors with different binding properties
and tissue distribution [80]. These distinct heterodimer combinations confer cell-cell and
cell-ligand specificity relevant to the cell and the environment in which it functions.
Through these interactions integrins trigger signaling pathways by clustering with other
integrins and activating kinases via the formation of focal adhesion complexes. These
functions of integrins play a role in cancer defining processes including tumor cell
growth, survival, migration, homing, metastasis and environmental mediated-drug
resistance.
The alpha and beta subunits form a non-covalently bound dimer, which consists
of an ectodomain that contains multiple domains with flexible linkers, a transmembrane
domain and a short cytoplasmic tail. The extracellular domain interacts with and binds to
ligands of the extracellular matrix. The transmembrane domain traverses the cell
membrane, linking the ectodomain and the cytoplasmic tail. The cytoplasmic tail acts as
an adaptor protein for intracellular signaling and as part of the scaffold, along with the
cytoskeleton, for the formation and growth of focal adhesions.
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Integrins are structurally classified based on the presence or absence of an I
domain in the α-subunit ectodomain. Within this domain is a five amino acid motif
termed the metal ion dependent adhesion site (MIDAS) which acts to coordinate ligand
binding [81]. Integrins lacking the I-like domain contain a similar domain within the βsubunit, termed the β I-like domain. Each individual integrin dimer generally recognizes
one specific ECM protein. There is some overlap between integrins and their ligand
recognition, as they recognize sequence motifs common among matrix proteins. For
example, the αV integrins, two β1 integrins (α5, α8) and αIIbβ3 all share the ability to
recognize ligands containing an RGD tripeptide active site contained by fibronectin and
vitronectin. The RGD-binding site is located at the interface between the β-propeller
domain and the β I-like domain and amino-acid residues from the two domains interact
directly with the RGD peptide [82]. α4β1, α4β7 and α9β1, on the other hand, bind to the
CS1 region of fibronectin through a LDV motif that is functionally related to RGD [83].
Integrins are known to exist in two major conformational states. They can exist in
an inactive or low affinity state or an active or high affinity state. Two models have been
proposed for the activation of integrins from a low affinity state to a high affinity state.
One model of integrin activation is the switchblade model in which the inactive state
corresponds to a bent conformation and the active state corresponds to a straight
conformation [84]. The other model is the deadbolt model in which the bent
conformation is maintained when integrins are activated but movements of the
transmembrane regions cause sliding of the extracellular stalks of the α and β subunits
[85].
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Integrins can also be activated bidirectionally, meaning both extracellular and
intracellular events can regulate activation. One way in which integrins can be activated
is by inside-out signaling. In inside-out signaling, adaptor proteins, like talin, bind to the
integrin β cytoplasmic tail and induce a conformational change in the ectodomain that
increases the integrins affinity for ligand [86]. Integrins can also be activated by outsidein signalling. In outside in signalling, binding of ligand to the integrins induces a
conformational change, including the separation of α and β stalk domains,
transmembrane domains which lead to the interaction of the β integrin cytoplasmic tail
with intracellular adaptor proteins like talin.
The integrin tails have no intrinsic kinase domain but rather serve as a site for
adaptor proteins to bind and help recruit various kinases that activate downstream
signaling. Talin and paxillin bind to β-integrin tails and recruit focal adhesion kinase
(FAK) and vinculin to the focal adhesions. α –actinin serves to crosslink both talin and
actin, which help to strengthen focal adhesions and promote focal adhesion growth [87].
Although some myeloma cells lack FAK, the tyrosine kinase pyk2 has been shown to
serve a similar function in cells lacking FAK expression [88]. The recruited kinases are
then able to govern many downstream kinases including AKT, ERK, and Jnk which are
important in multiple myeloma cell cycle progression, growth, survival, and migration.
Integrin Expression in Multiple Myeloma
Of the 18 alpha and 8 beta integrin subunits that have been identified very few
have been shown to have significant expression in MM cells. Different studies have been
done to try to identify the important integrin subunits in MM cells. In one study, it was
shown that MM cells extracted from bone marrow express no alpha 2 integrin, and
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almost no alpha 6 integrin, although they have variable expression of alpha 4, alpha 5,
and beta 1 integrins [89]. Another study showed that in the cell lines studied, there was
high expression of alpha 4 and beta 1 integrin expressed with minimal expression of
alpha 3 integrin and no expression of alpha 2 integrin and alpha 6 integrin [90]. Yet
another study focused on other cell lines showed high levels of alpha 4 integrin, alpha 5
integrin, beta 1 integrin and beta 7 integrin [69]. Consistent in these studies is the high
expression of alpha 4 integrin, beta 1 integrin and beta 7 integrin with some myeloma cell
lines expressing alpha 5 integrin. In addition to these integrins the alphaLbeta2 integrin
and the alphavbeta3 have also been shown to be expressed on MM cell lines.
The α4β1 (very late antigen 4 or VLA-4), α5β1 (VLA-5), and α4β7 heterodimers
are major integrin heterodimers associated with MM cells. VLA-5 has been shown to
mediate cell adhesion to the ECM protein FN while the α4β7 integrin has been shown to
mediate cell adhesion to the MAdCAM-1 receptor of bone marrow stroma cells. VLA-4
is unique among integrins as it has been shown to be the only heterodimer that mediates
cell-ECM as well as cell-cell interactions [91]. VLA-4 has been shown to bind to the CS1 region of FN as well as to VCAM-1 via a separate binding site. The α4 integrin is also
unique in it is the only integrin to be expressed on the plasma membrane in two distinct
forms, the intact (150 kDa) alpha 4 subunit and a cleaved form which consists of two
noncovalently associated fragments (80 and 70 kDa). Even though cleavage of α4 has
been shown to be increased after T cell activation, previous binding studies using the
intact and cleaved subunits showed no alteration in VLA-4 binding function [92]. In
addition to existing in two distinct isoforms on the cell surface of myeloma cell lines,
there was shown to be a difference in VLA-4 expression in relapsed MM patients
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compared to newly diagnosed patients. In a study done by Schmidmaier, it was shown
that VLA-4 and VCAM expression was higher in pre-treated patients than in chemonaive patients and the expression levels increased with the number of chemotherapy
regimens [93].
In addition to patient samples α4, α5, β1, and β7 integrin levels have been studied
in sensitive and drug resistant MM cell lines. In sensitive 8226/s cell lines, there was
minimal expression of α4 and β7 integrins with high expression of α5 and β1. 8226/s
was then chronically treated with melphalan and doxorubicin to develop the isogenic
drug resistant cell lines 8226/LR5 and 8226/dox6 cell lines respectively. As the cell lines
are selected for resistance the surface expression of the integrins are changed. In the drug
resistant cell lines α4 and β7 integrin expression is increased while α5 integrin expression
is decreased, indicating that an increase in α4 integrin expression is correlative for drug
resistance in MM cells [69]. In addition to increased integrin expression being a
determinant for drug resistance to therapeutic agents, integrin function associated with
VLA-4 was also shown to be changed in drug resistant cell lines. In the melphalan
resistant MM cell line U226/LR7 there were similar levels of α4 integrin in the resistant
line compared to the U226 sensitive line. However, U266/LR7 cells adhere to FN at a
significantly higher rate than U266 cells in a VLA-4 dependent fashion and correlated
with CAM-DR to melphalan [94]. β7 integrin mRNA expression was also screened in a
panel of MM cell lines. Results showed that cells with a t(4;14)(H929,OPM2) or t(14;16)
(MM1S) that correlates with poorer prognosis expressed the highest levels of β7 integrins
[95].
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As VLA-4 is shown to have higher expression on drug resistant cell lines and
relapsed/refractory patients, therapeutics that target or lower VLA-4 levels have been
investigated in MM cell lines. For example, a study showed that the highly successful
MM therapeutic bortezomib reverses CAM-DR and sensitizes cells to dexamethasone in
the coculture environment in part by downregulating the expression of VLA-4 [96].
Antibodies against α4 integrin have also shown to have decrease myeloma growth in
vitro and in vivo. The monoclonal antibody PS/2 was shown to inhibit the growth of
GFP-expressing 5TGM1 cells in C57Bl/KaLwRij mice [97]. The humanized monoclonal
antibody natalizumab was also shown to disrupt the binding of MM cells to FN and
chemosensitize cells to bortezomib [98]. Micellular nanoparticles targeting α4 integrins
have also been developed and have been shown to overcome CAM-DR [99]. In addition
to targeting VLA-4, other integrins have been an attractive target for developing new
therapeutics to target MM as well as other cancers.
Integrin Targeted Therapeutics
Targeting integrins is of great interest in the treatment and prevention of cancer.
Antibodies, peptidomimetics, and small molecule antagonists have all been utilized in
order to target integrins. Each type has its own advantages and disadvantages.
Antibodies are the most widely used strategy in developing integrin targeting drugs.
Antibodies are advantageous as they have very high target specificity and affinity,
leading to a decrease in off target effects. Antibodies also have high circulation times
compared to small molecule inhibitors and peptides. The disadvantages for antibodies
include the need for intravenous administration and the propensity for host
immunogenicity. Peptide-based drugs have high target affinity and specificity but have
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limited stability. Techniques can be utilized to increase stability and decrease proteolytic
cleavage such as cyclization of peptides or the use of D-amino acids. Small molecule
inhibitors have high stability and can be administered orally but have low selectivity in
integrins. There have been promising results utilizing antibodies, peptidomimetics and
small molecular inhibitors in targeting integrin heterodimers shown to be expressed in
MM cells like VLA-4, VLA-5 and αVβ3.
Antibodies that target α4, α5 and αVβ3 integrins have been shown to have success
in decreasing tumor burden and decrease integrin mediated CAM-DR. The anti-α4
integrin antibody, natalizumab, has been shown to prevent the adhesion of leukocytes to
the receptors VCAM-1 and MAdCAM-1 and is currently used in the treatment of
multiple sclerosis and Crohn’s disease. As MM cells have been shown to express high
levels of α4 integrin, newer studies have looked into the effect that Natalizumab has on
MM cell growth in the bone marrow microenvironment. It was shown that Natalizumab
blocked VEGF and IGF-1 induced MM cell migration and also chemosensitized MM
cells to bortezomib [98]. Volociximab, a monoclonal antibody against VLA-5, has also
been shown to inhibit angiogenesis and impede solid tumor growth. It is currently in a
phase II clinical trial in solid renal cell carcinoma and is also being investigated in the
treatment of macular degeneration [100]. In addition several therapeutic antibodies are
currently being investigated that target the αVβ3 integrin. Vitaxin is a humanized mouse
monoclonal antibody that blocks angiogenesis and induces apoptosis in advanced solid
tumors and is currently in phase I clinical trials. CNTO 95 has also been shown to inhibit
melanoma cell adhesion and inhibit tumor growth in mouse xenografts. In a phase I
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clinical trial an analysis of a post-treatment biopsy showed decreased expression of bcl-2
after treatment and it is being investigated in phase II clinical trials [101].
Peptidomimetics targeting integrins are also being looked at as a means to block
tumor growth and progression. One of the first peptide sequences shown to block the
interaction between integrins and FN was the sequence RGD. In addition to mediating
the interaction between the cell and FN, cyclized RGD containing peptides were also
shown to directly induce apoptosis in breast cancer cells by directly binding to and
activating caspase-3 [102]. Other peptides have been developed with the RGD sequence
and have been shown to have anti-tumor effect on cancer cells. Cilengitide is a cyclic
pentapeptide containing the RGD sequence and was selected for its capacity to
specifically inhibit the αVβ3 and αVβ5 integrins [103]. Cilengitide is currently being
tested in phase II clinical trials for patients with lung and prostate cancer. It has been
shown to have anti-tumor effect in newly diagnosed glioblastomas with 69% of patients
being progression free after 6 months [104]. Cilengitide is currently in a phase III
clinical trial for the treatment of glioblastoma. ATN-161 is a non-RGD-based peptide
that has been shown to block the growth of breast cancer cells in vivo [105]. ATN-161
was tested in a phase I clinical trial of patients with advanced solid tumors with 1/3 of
patients treated showed prolonged stable disease [106]. In MM cells a VLA-4 antagonist
peptide has been developed that when conjugated to doxorubicin and nanoparticles
blocks MM cell adhesion and induces apoptosis in a xenograft model.
Small molecule antagonists targeting integrins have also been shown to inhibit
integrin signaling and decrease cancer metastasis. The VLA-5 small molecule inhibitor
JSM6427 was shown to reduce FN-induce ERK phosphorylation which has been shown
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to be a signal associated with CAM-DR and further studies are ongoing for its effects on
cancer cells [107]. The αVβ3 integrin small molecule antagonist S247 has been shown to
inhibit breast cancer bone metastasis and decreased colon cancer metastasis. In addition,
it was shown to inhibit the development of colon cancer metastases and growth to the
liver in an in vivo model [108]. A different αVβ3 integrin small molecule antagonist,
PSK1404, was also shown to inhibit breast and ovarian bone metastases in a murine
mouse model. In addition, PSK1404 was shown to inhibit osteoclastic activity in the
bone marrow microenvironment which substantially decreased tumor initiated bone
destruction [109].
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Chapter 4: Cell Death Pathways
Apoptosis
Different kinds of cell death are distinguished by distinct morphological criteria,
and are classified into distinct modes of cell death. Three of the most commonly
classified modes are defined as apoptosis, autophagy and necrosis. Apoptosis has been
determined to be an important mode of programmed cell death in cells with activation of
caspases leading to cell shrinkage, chromatin condensation and cell blebbing.
Autophagy is defined as a process in which the cell degrades its own components through
the merging of the autophagosome and lysosome and is known to occur via cell
starvation or extreme cell stress. Necrosis is usually defined as a passive and energyindependent form of cell death which results in swelling of cellular organelles and loss of
plasma membrane integrity but there are some forms of necrosis, like necroptosis, which
are now classified as a form of programmed cell death. In apoptosis, two classes of
proteins play a distinct role; the Bcl-2 family of proteins which are responsible for
mitochondrial integrity and the cysteinyl aspartate-specific proteases or caspases, which
are responsible for the direct execution of cells.
Caspases are divided into initiator caspases (caspase-2, -8, -9, -10) and
executioner caspases (caspase-3,-6, -7). These caspases can be activated by either the
intrinsic or extrinsic cell death pathways. The intrinsic cell death pathway is activated by
internal cell stimuli such as DNA damage or internalized cytotoxic drugs and acts
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through release of proteins from the mitochondria which are controlled by the Bcl-2
family of proteins. Under normal conditions, anti-apoptotic Bcl-2 family members
sequester the pro-apoptotic proteins Bax and Bak from dimerizng. During cellular stress,
Bcl-2-homology 3 (BH3)-only proteins, like Bim, are activated and bind the antiapoptotic
Bcl-2 family members, leading to the dimerization of Bax and Bak and subsequent
formation of a channel on the mitochondrial membrane where cytochrome c is released.
Cytochrome c associates with Apaf-1 and helps with the recruitment and activation of
procaspase-9 [110]. Other proteins like Smac/DIABLO and Omi are released from the
mitochondria and help promote caspase 9 activation by inhibiting inhibitors of apoptosis
protein (IAP) activity [111]. Activated caspase 9 cleaves and activates executioner
caspases like caspase-3 which causes chromatin condensation and apoptotic cell death.
The extrinsic pathway of apoptosis is activated by external stimuli and involves
the stimulation of death receptors belonging to the tumor necrosis factor receptor (TNFR)
family, such as itself, Fas and TRAIL-R. The binding of Fas ligand to Fas receptor
results in the association of the adaptor protein FADD while the binding of TNF ligand to
TNFR results in the association of the adaptor protein TRADD and subsequent
recruitment of FADD [112]. FADD associates with procaspase 8, resulting in the
formation of a death-inducing signaling complex (DISC). Caspase 8 is then activated
which triggers the execution phase of apoptosis. Like IAP inhibition of procaspase 9 the
extrinsic apoptotic pathway can also be inhibited. The protein c-FLIP has been shown to
bind to FADD and procaspase 8, rendering the cell death pathway useless [113].
Many drugs used in treating MM induce apoptosis. The DNA alkylating drug,
melphalan, for example, has been shown to disrupt the interaction of Mcl-1 and Bim,
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thereby releasing Bim which leads to Bax activation and cytochrome c release [114].
The glucocorticoid, dexamethasone, has also been shown to induce apoptosis in multiple
myeloma cell lines. As the MM1R cells gain resistance to dexamethasone, they lose
expression of the glucocorticoid receptor which binds dexamethasone. Reexpression of
the glucocorticoid receptor in dexamethasone resistant MM1R cells induced Bim
expression and dexamethasone apoptosis, indicating that dexamethasone also induces
apoptosis in MM cells in a Bim dependent manner [115]. The proteasome inhibitor
bortezomib has been shown to trigger caspase activation in retinoblastoma and chronic
lymphocytic leukemia as a primary agent. In addition to directly causing activation of
caspases, bortezomib has also been shown to sensitize MM to apoptosis inducing drugs
like dexamethasone and melphalan [116]. In addition to sensitizing agents that induce
apoptosis by the intrinsic apoptotic pathway, bortezomib has also been shown to sensitize
MM cells to cell death by the extrinsic pathway drugs like TRAIL by decreasing the
protein expression of the antiapoptotic protein c-FLIP [117]. New classes of compounds
are being developed and tested that induce apoptosis in MM cells in addition to
established therapeutics. For example, arsenic trioxide has been shown to activate
caspases in MM cells [118]. Utilization of different compounds that target the apoptotic
pathway via different mechanisms could potentially reverse drug resistance in MM that
occurs because of the microenvironment like the upregulation of antiapoptotic proteins
Mcl-1, Bcl-2, c-FLIP and XIAP or downregulation of proapoptotic proteins like Bim.
Utilizing drugs that target the other cell death pathways like autophagy and necrosis
could also prove to be useful in treating MM patients in combination with apoptotic
inducing drugs.
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Autophagy
Autophagy is a catabolic pathway that allows cells to degrade and recycle cellular
components. Autophagy is unique among cell death pathways as induction of autophagy
has been shown to correlate with both cell survival and cell death. The presence of
autophagic vacuoles is commonly seen in dying cells, often accompanying apoptotic and
necrotic cell death. In fact, there have been shown to be interconnections that exist
between autophagy and apoptotic and necrotic cell death. For example, the anti-apoptotic
protein Bcl-2 has been shown to repress autophagy by binding to the autophagy
stimulating protein Beclin-1 [119]. Active caspase 8 has also been shown to cleave
Beclin-1 into 2 fragments, with one of the fragments translocating to the mitochondria
and facilitates release of cytochrome c [120]. Even though the outcome of autophagy
usually reflects a pro-survival function, autophagy can induce cell death under certain
conditions. RNA interference (RNAi) directed against 2 autophagy genes, atg7 and
beclin 1, blocked cell death in mouse L929 cells treated with the caspase inhibitor zVAD
[121]. Further, RNAi against atg5 and beclin 1 blocked death of bax–/–, bak–/– murine
embryonic fibroblasts (MEFs) treated with etoposide [122]. Notably, in both of these
studies RNAi blocked the death of cells whose apoptotic pathway had been crippled,
implicating autophagy as a cell death mechanism when apoptosis is inhibited.
Three types of autophagy have been described; chaperone-mediated autophagy,
microautophagy and macroautophagy. Macroautophagy has been the best described
autophagic process and is usually referred to as just autophagy. Autophagic signaling has
been shown to be regulated by mTOR, a protein kinase that is important in controlling
translation and cell-cycle progression. When mTOR is inhibited by stimuli such as
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nutrient starvation or rapamycin, the ULK-Atg13-FIP200 complex is formed, with the
formation of this complex leading to the induction of the formation of the
autophagosome. The synthesis of the autophagosome also requires vesicle nucleation,
which is initiated by the formation of the PI3KC3 (Vps34)-complex, of which Beclin-1 is
a member. Once this complex is activated, phosphatidylinositol 3-phosphate (PI3P) is
generated and helps to recruit other proteins that elongate the autophagosome. The
Atg12-Atg5-Atg16 complex is recruited which plays a role in vesicle curvature while the
autophagic marker LC3 is lipidated and specifically binds to the autophagosome
membrane. After all of these events occur, the autophagosome fuses with a lysosome,
releasing its content into the lysosome to be degraded by hydrolases.
Autophagy is shown to be important in diseases where protein production is
instrumental in characterizing the disease, like MM. It is believed that the ongoing
induction of autophagy seen in some cell lines protects cells from the accumulation of
misfolded proteins and is shown to be a survival mechanism in MM. Many drugs that
induce apoptosis in MM cells are also shown to induce autophagy. For example, the
apoptosis inducing DNA-damaging drugs doxorubicin and melphalan are also able to
trigger Beclin 1-regulated autophagy in the human MM cell lines H929 and RPMI 8226
with the silencing of beclin-1 or Atg5 augmenting their proapoptotic activity [123].
Bortezomib was also shown to induce autophagy in MM cells but inhibiting autophagy
with the lysosomotrophic agent chloroquine did not increase bortezomib induced cell
death [124]. However, bortezomib is shown to exhibit synergistic effects in combination
with agents that uncouple the aggresome, a proteinaceous inclusion body that forms when
cellular degradation machinery is impaired, and autophagy pathways. Tipifarnib, a
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farnesyl transferase inhibitor that also inhibits the oncogene Ras, has been shown to
synergize with bortezomib in 8226 MM cells in this manner [125]. From most reports, it
is shown that induction of autophagy produces a survival effect in MM cells and
inhibiting this pathway either in conjunction with uncoupling the aggresome in the case
of bortezomib or without uncoupling the aggresome in the case of doxorubicin and
melphalan sensitizes the cells to established therapies.
Necrosis
Necrosis is predominantly described as an accidental or uncontrolled form of cell
death and is characterized by organelle swelling, followed by loss of cell membrane
integrity and release of cellular components from the cell. As necrosis is not thought of as
being tightly regulated, key cellular processes are characterized as being important for the
induction of necrosis instead of activation of executioner proteins. The key bioenergetic
events that are usually implicated in necrosis are; increased mitochondrial dysfunction,
adenosine triphosphate (ATP) depletion, depletion of intracellular nicotinamide adenine
dinucleotide (NAD+), increased levels of intracellular calcium, and increased generation
of reactive oxygen species (ROS). Evidence is beginning to show that in addition to these
key processes, some modes of necrosis can also be a tightly regulated event, with forms
of necrosis such as necroptosis appearing to be programmed modes of cellular death.
There also have been shown to be interconnections with necrosis and apoptosis and
autophagy, as some of the key mediators of necrosis have been shown to disrupt the
mitochondria, extracellular death receptors such as TNFR and lysosomes important in
autophagy.

36

Mitochondrial dysfunction is a key event that occurs during necrosis. In normal
cells, a membrane potential is generated across the mitochondrial inner membrane as
protons are pumped across the inner membrane. This process is responsible for the
generation of ATP by oxidative phosphorylation. Certain stimuli such as an increase in
intracellular calcium or an increase in intracellular ROS have been shown to open the
mitochondrial permeability transition (mPT) pore on the mitochondria inner membrane.
Opening of the mPT pore causes a cell to stop the generation of ATP by oxidative
phosphorylation. Experiments have shown that a transient opening of the mPT pore
induces apoptosis by release of apoptotic factors such as cytochrome c or apoptosis
inducing factor (AIF) but persistent opening of the mPT has been shown to induce
necrosis [126]. MPT induced necrosis is regulated by the protein cyclophilin D (cyD)
and inhibiting cyD with cyclosporin A has been shown to inhibit the MPT and inhibit
calcium induced necrosis [127].
In addition to disrupting key metabolic events that produce ATP through
oxidative phosphorylation, necrosis has also been shown to occur through disruption of
ATP that is produced during glycolysis. Poly (ADP-ribose) polymerase (PARP) is a
nuclear protein known to be activated following single-strand DNA breaks and is a signal
to recruit other DNA-repair enzymes such as DNA ligase III to repair the DNA. In order
to generate ADP-ribose monomers integral to the DNA repair process, activated PARP
depletes intracellular stores of NAD+ by converting NAD+ into nicotinamide adenine
mononucleotide (NAM). Overexpression of PARP has been shown to induce necrosis by
depleting cellular NAD+ levels in cells that depend on glucose metabolism. Activated
PARP converts NAD+ into NAM. Since NAD+ cannot cross the mitochondrial
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membrane activated PARP selectively inhibits glucose metabolism, which has been
shown to induce necrosis [128].
Increases in intracellular Ca2+ have also been shown to initiate necrosis. As Ca2+
is a secondary messenger for many integral cell processes, levels of Ca2+ in the cell are
tightly regulated. Under normal physiological conditions the concentration of Ca2+ is
determined to be around 1.2 mM in the extracellular matrix and around 0.1 µM in the
cytosol with most of the excess intracellular Ca2+ stored in the endoplasmic reticulum
(ER). In order to maintain Ca2+ homeostasis, Ca2+ is either able to enter or leave the cell
through distinct Ca2+ channels on the plasma membrane. Ca2+ levels in the cell are also
maintained by storage or release of intracellular Ca2+ stores located in the endoplasmic
reticulum(ER). If intracellular stores of Ca2+ are increased too quickly, the mitochondria
will also store excess Ca2+. If the concentration of Ca2+ is increased to too high a level
(>1µM), the mitochondria becomes overloaded with Ca2+ [129]. Mitochondrial Ca2+
overload has been shown to lead to opening of the mPT pore and ATP depletion, which
in turn leads to necrosis [130]. Ca2+ is also responsible for activation of the Ca2+
dependent proteases calpains. Calpains have been shown to induce lysomal membrane
permeability (LMP) of lysosomes, thereby releasing lysosomal enzymes into the
cytoplasm and inducing necrotic cell death [131].
During oxidative phosphorylation in the mitochondria, electrons frequently
escape from the electron transport chain. The reaction of the escaped electron and
oxygen produces oxygen radicals, which are converted into ROS. These ROS consist of
molecules including superoxide, hydrogen peroxide (H2O2), and nitric oxide (NO). ROS
are usually neutralized by enzymes such as superoxide dismutase and glutathione
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peroxidase or by reacting with a scavenger such as glutathione. When the balance
between ROS and their scavengers is disturbed, an excess of ROS has been shown to
damage cellular biomolecules including DNA, proteins and lipids. For example, it was
shown that excess mitochondrial ROS have been shown to cause cleavage of DNA
strands, cross-linking and oxidation of purines resulting in necrosis [132]. In addition to
causing necrotic cell death through double stranded DNA damage, mitochondriaproduced ROS have also been shown to cause necrotic cell death of fibrosarcoma cells by
TNFα [133].
In addition to studying key bioenergetic events that initiate necrosis, studies are
also being done to determine instances of regulated necrotic cell death. One such form of
programmed necrosis, necroptosis, has been shown to be activated by ligation of cell
death receptors such as FAS, TNFR and TRAILR. Upon binding of ligands such as
TNFα, the TNFR forms trimers and recruits several death domain-containing proteins to
form the DISC. Key proteins present in this complex are FADD, RIP1, RIP3, and
caspase 8 [134]. If caspase 8 is not inhibited by proteins such as IAPs, caspase 8 cleaves
RIP1 and RIP3 and induces caspase dependent apoptosis. If caspase 8 is inhibited, as has
been previously shown with RNAi, RIP1 and RIP3 become phosphorylated and induce
necroptosis [135]. Phosphorylated RIP1 causes PARP activation, ATP depletion,
activation of ROS and an increase in intracellular calcium, all considered to be hallmarks
of necrosis.
Necrosis inducing drugs are not currently heavily used in MM treatment as most
of the drugs used are shown to target the apoptotic pathway in MM cells. Some drugs,
however, induce a multimodal mechanism of cell death in MM cells. Doxorubicin has
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been shown to induce the formation of ROS in addition to inducing autophagy and
apoptosis. In fact, at low doses of doxorubicin, it was shown that the primary mode of
cell death was determined to be necrosis instead of apoptosis [136]. ATO has also been
shown to induce mediators of necrotic cell death as well as apoptosis by increasing ROS
production and loss of mitochondrial membrane potential [118]. A novel antibiotic
active against nutrient-starved oncogenesis, kigamicin, is one compound that has been
shown to induce necrosis in MM cells. One interesting note of this study was that
kigamicin produced higher levels of cell death in melphalan resistant cell lines compared
to the parental lines, indicating that agents that cause necrosis may be useful in causing
cell death in cells that have become resistant to apoptosis inducing drugs [137]. As the
ability of tumor cells to evade apoptosis has been well classified as a cause of drug
resistance in MM cells, drugs that target other cell death pathways may become more
useful in treating MM.
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Chapter 5: Ca2+ Signaling
Ca2+ Homeostasis
Positively charged calcium ions (Ca2+) along with negatively charged phosphate
ions are considered two of the most important secondary messengers that regulate
signaling in cells. As Ca2+ binds to thousands of proteins in order to mediate these
signaling events, such as protein association, function and localization, Ca2+ needs to be
tightly regulated inside the cell. As such, channels are present on the plasma membrane,
ER and mitochondria whose function is to control the uptake and release of Ca2+ in order
to ensure that the ideal cytoplasmic concentration (~100 µM) is maintained in resting
cells. The plasma membrane contains 3 distinct types of Ca2+ influx channels, voltagegated, ligand-gated and store operated channels (SOC), which are responsible for Ca2+
intake into the cell. In addition, the plasma membrane also contains the plasma
membrane Ca2+ ATPase (PMCA) pump and a Na2+/Ca2+ exchanger that are responsible
for the efflux of Ca2+ out of the cell. The sarcoendoplasmic reticular Ca2+ ATPase
(SERCA) causes an influx of Ca2+ into the ER while the 1,4,5- inositol triphosphate (ip3)
receptor and ryanodine receptor (RyR) are responsible for release of intracellular ER
stores into the cytoplasm. Finally, the Ca2+ uniporter is responsible for Ca2+ influx into
the mitochondria while the mPT pore is responsible for efflux of Ca2+ into the cytoplasm.
Voltage-gated Ca2+-selective channels (CaVs) are common in many different
types of cells but their activity has mainly been studied in excitable cells; like neurons,
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cardiocytes, muscle tissues and endocrine cells. CaVs are the fastest family of Ca2+
channels with a million Ca2+ ions per seconds crossing the channel gradient. The
channel’s receptor contains a helix-turn-helix loops containing positively charged
arginine residues, which are opened following a change in voltage [138]. Ligand-gated
Ca2+ channels are opened or closed by the direct binding of a ligand to the channel itself.
Binding of the ligand opens the channel which allows influx of Ca2+ ions into the cell.
These channels are present on most cells and there is a belief that these channels play a
role in cell-cell communication between cells but most of the studies done on these
channels have been performed in sensory cells with neurotransmitter ligands. SOCs
represent the last family of plasma membrane Ca2+ influx channels. In many
nonexcitable cells, there is little Ca2+ influx across the plasma membrane. As Ca2+ is
constantly seeping out of the ER into the cytoplasm and is frequently released from the
ER to mediate Ca2+ signaling pathways, ER calcium stores are frequently found to be
depleted. Upon ER Ca2+ depletion, stromal interaction molecule 1 (STIM1) senses the
depletion and aggregates in the ER just below Orai1 on the plasma membrane [139].
Orai1 is an essential pore subunit of the calcium-release-activated calcium (CRAC)
channel and is responsible for the influx of Ca2+ by SOCs [140].
An important mechanism of Ca2+ signaling is the release of Ca2+ from the ER
reticulum through two distinct receptors, the ip3 receptor and the RyR. G proteincoupled receptors (GPCR) and receptor tyrosine kinases (RTK) are both located at the
plasma membrane of eukaryotic cells and serve a primary function of transducing
extracellular stimuli into intracellular signals. 2 specific subtypes (Gq/11) of GPCR have
been shown to activate phospholipase Cβ while RTKs have been shown to activate
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phospholipase Cγ. Both isoforms of phospholipase c (PLC) cleave phosphatidylinositol
4,5 biphosphate (PIP2) into ip3 and diacylglycerol. Ip3 binds to the ip3 receptor on the
ER membrane and allows diffusion of Ca2+ from the ER to the cytosol. Calcium release
from the ER has been shown to occur by periodic discharges of Ca2+ from the ER [141].
RyR are different from ip3 receptors as the primary agonist of RyRs is Ca2+ itself. When
cytoplasmic levels of Ca2+ are determined to be low, RyRs are opened to allow efflux of
Ca2+ from the ER. When cytoplasmic levels of Ca2+ are increased to high levels (>1mM)
the channel is completely inhibited.
Like the ER, mitochondria can store Ca2+ but the mechanism in how the
mitochondrion regulates the influx of Ca2+ is different. While Ca2+ diffuses through the
uniporter into the outer mitochondrial membrane, it crosses into the inner mitochondrial
membrane from ion exchange channels, where Na2+ and H+ created by oxidation of
NADH are exchanged for Ca2+ ions. An increase in Ca2+ levels in the mitochondria
stimulates several dehydrogenases in the Krebs cycle and boosts ATP production along
with ROS formation. An increase in matrix Ca2+ also activates the mPT pore, which
causes release of calcium back into the cytoplasm.
Calcium Interaction with Apoptosis and Autophagy
Ca2+ has long been shown to play a role in necrotic cell death. As discussed
earlier, high concentrations of intracellular Ca2+ can overload the mitochondria, causing
an increase in ROS, ATP depletion and mitochondrial dysfunction. Ca2+ has also been
shown to activate proteases like calpains which induce necrotic cell death. In addition to
playing a role in mediating cellular necrosis, Ca2+ has also been shown to play a role in
interacting with proteins that mediate apoptotic and autophagic cell death. Early studies
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showed that different concentrations of intracellular calcium can activate either apoptosis
or necrosis. Lower levels of Ca2+ (200-400 nM) have been shown to trigger apoptosis
while higher levels of Ca2+ (>1 µM) have been shown to induce necrosis [129]. The ip3
receptor has been shown to bind to Bcl-2 on the ER membrane, with Bcl-2 levels
determining whether Ca2+ oscillations will lead to cell survival or cell death. Ca2+ has
also been shown to be regulated by the proapoptotic proteins, Bax and Bak. Recent
evidence has also shown the ability of Ca2+ to help regulate autophagy via ip3r forming a
complex with beclin-1 on the ER.
Bcl-2 has been shown to localize to the ER membrane in addition to localizing to
the mitochondria. Bcl-2 has been shown to directly interact with the ip3 receptor on the
ER membrane and this interaction inhibits ip3 dependent calcium efflux [142]. Further
analysis indicated that the BH4 domain of Bcl-2 associates with a region within domain s
of the ip3r [143]. A result of this interaction is that ER-targeted Bcl-2 (Bcl-cb5) was able
to inhibit apoptosis to agents that deplete the mitochondrial membrane like ceramide
[144]. Bcl-2 has also been shown to bind to the Ca2+ dependent phosphatase calcineurin
which has been shown to phosphorylate the ip3 receptor. It is speculated that bcl-2
facilitates dephosphorylation of ip3 receptor by interacting with calcineurin as ip3
receptor phosphorylation is decreased in Bcl-2 overexpressing cells [142]. Although Bcl2 can inhibit ip3 induced calcium oscillations that promote apoptosis, it can also enhance
ip3 induced Ca2+ oscillations that promote survival. In B cell lymphocytes, Bcl-2
enhances Ca2+ oscillations by sensitizing the cells to lower levels of ip3, which leads to
increased mitochondria metabolism and cell survival [145].
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Ca2+ is also shown to be regulated by proapoptotic Bcl-2 family members. Like
Bcl-2, Bax and Bak have also been shown to localize to the ER membrane where they
have been shown to have a role in Ca2+ release from the ER. When Bax/Bak is knocked
out in cells, ER luminal Ca2+ levels are decreased compared to wild type cells. This
decrease in ER calcium compromises ER Ca2+ release as well as mitochondrial uptake
[146]. In another study, the use of a Bax inhibitor facilitated the release of Ca2+ from the
ER, depleting the ER pool [147]. These studies infer Bax/Bak prevents Bcl-2 mediated
leaking of Ca2+ from the ER. When Bax/Bak are overexpressed, however, they induce an
increase in Ca2+ levels followed by cytochrome c release and apoptosis [148]. There is
also evidence that other BH-3 only proteins, such as Bim and Noxa, may have a role in
mediating Ca2+ function. T-cells deficient in Bim have been shown to have impaired
Ca2+ release following activation, which is associated with increased binding of Bcl-2 to
ip3 receptor on the ER membrane, indicating a role of Bim in enhancing Ca2+ release
from the ER by sequestering Bcl-2 [149]. The mitochondrial targeting region of Noxa
was shown to increase mitochondrial permeability and release Ca2+, while a peptide
developed to correspond to the same region was shown to initiate necrotic Ca2+
dependent cell death [150].
Ca2+ signaling also plays a role in regulating the induction of autophagy.
Previous studies showed that Ca2+ was mobilized after stimulated with agents such as
thapsagargin and ionomycin and that the Ca2+ mobilization induced autophagy. The
intracellular calcium chelater BAPTA-AM was also shown to inhibit the aggregation of
GFP-LC3 aggregates, indicating that autophagosome formation was autophagy
dependent [151]. The ip3 receptor has also been shown to play a role in regulating
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autophagy. Beclin-1 has also shown to be in a complex with Bcl-2 and ip3 receptor, with
the disruption of this complex with the ip3 receptor inhibitor Xestospongin B sufficient
for the induction of autophagy [152]. Knocking down of the ip3 receptor was also
sufficient to induce conversion of LC3I to LC3II [153]. In addition to inhibiting the ip3
receptor, direct inhibition of ip3 by L-690,330 was enough to induce autophagy [154].
Multiple cytotoxic agents have been identified that function to disrupt Ca2+
homeostasis leading to cell death. One such drug is cisplatin, a DNA crosslinking drug
used to treat several different kinds of cancer including MM. Cisplatin has been shown
to cause an ip3 receptor-dependent increase in cystolic Ca2+ prior to induction of
apoptosis. Knocking down of the ip3 receptor in cancer cell lines also mediates
resistance to cisplatin induced cell death [155]. In MM, cisplatin is used in combination
with dexamethasone and etoposide as an effective regimen to treat relapsed/refractory
patients. Staurosporine, a protein kinase inhibitor, also promotes Ca2+ leak from the ER
by the cleavage of ip3 receptor. Inhibiting cleavage of the ip3 receptor by transfection of
mutant ip3 receptors in B cells lacking ip3 receptors was shown to inhibit apoptotic
induction by staurosporine [156]. Staurosporine is a precursor to PKC412 which is in
phase III trials for AML and exhibits activity in MM cells. Thapsigargin is another
cytotoxic agent that decreases the ER calcium pool by directly inhibiting SERCA pumps.
Thapsigargin has been studied in MM cells alongside bortezomib has they have both
been such to cause ER stress and induce autophagy. Thapsigargin produced a synergistic
effect in MM cells when used in combination with an inhibitor of autophagosome
formation, 3-methyladenine (3-MA), while bortezomib showed an antagonistic effect
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with 3-MA [124]. Bortezomib and thapsigargin also have a synergistic effect in inducing
cell death in pancreatic cancer cell lines when used in combination [157].
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Chapter 6: HYD1
Development of HYD1 in Prostate Cancer Cells
HYD1 was first identified as a peptide that could support tumor cell adhesion and
inhibit tumor cell adhesion to immobilized ECM proteins. In order to identify peptides,
they used a ‘one-bead one-compound’ combinatorial screening method. In this method,
coupling cycles were used to attach amino acids to beads. Because each bead only
encountered one amino acid at each coupling cycle, when the reaction was driven to
completion only one distinct peptide was displayed on each bead [158]. Utilizing this
approach, several L-amino acid containing peptides were selected based upon the ability
of prostate tumor cells to bind to the immobilized peptide [159]. As D-amino acid
containing peptides are able to resist being degraded by proteases, screening with a Damino acid containing peptide library was also done. Following this screening, two
peptides, RZ-3 and HYD1 (kikmviswkg), were discovered to be biologically active
peptides that can themselves inhibit tumor cell adhesion to immobilized ECM proteins
[160].
HYD1 and it’s scrambled derivative HYD1s (wiksmkivkg) were further tested on
their ability to be able to inhibit tumor cell motility on laminin-5. HYD1 was shown to
block migration of prostate cancer cells on laminin-5 while HYD1s did not. HYD1 was
also to inhibit adhesion to immobilized laminin-5 to the same extent as integrin blocking
antibodies to α3, α6, and β1. It was also shown to interact with α6 and α3 integrin
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subunits, but not α2 integrins in prostate cancer cells, while HYD1s did not interact with
any of the integrins tested. Depletion of β1 integrin containing integrins from membrane
lysates of DU-145 cells removed the ability for HYD1 to bind with the α6 integrin,
indicating that the peptide interacts with the α6β1 dimer. Incubation with HYD1 also
increased the activation of FAK and phosphorylation of MEK, with the greatest signal
occurring at 15 minutes after incubation. Lastly, treatment with HYD1 was shown to
display increased filamentous actin and an accumulation of actin at the cell membrane
[161]. In a different report, alanine substitution analysis and a peptide deletion strategy
were used to determine the minimal element of HYD1 necessary for bioactivity in a
prostate cancer cell lines. Bioactivity was measured by assays of cell adhesion, migration
and ERK signaling. The sequence of HYD1 necessary to support cell adhesion was
kmvixw, the block to migration required xkmviswxx and activation of ERK signaling
required ikmviswxx, where x is a placeholder peptide [162].
HYD1 activity in MM cells
As HYD1 was shown to block cell adhesion to laminin 5 in a β1 integrin
dependent manner, studies were done to see if HYD1 could block adhesion of MM cells
to the ECM protein, FN [163]. HYD1 indeed blocked adhesion of MM cells to FN at a
concentration of 50 µg/ml. Similar inhibition of adhesion to FN was seen when MM
cells were treated with a blocking α4 integrin antibody. In contrast, HYD1 did not block
MM cell adhesion to bone marrow stromal cells, a finding that was consistent with a β1
blocking antibody, suggesting that multiple cell adhesion molecules may be necessary to
regulate adhesion of MM cells to bone marrow stroma. Even though HYD1 did not block
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U266

Figure 4: HYD1 induces cell death as a single agent in MM cells. (A,C,D) H929,
U266 and 8226 cells were treated with varying concentrations of HYD1 for 6 hrs and
Annexin V positivity was measured. (B) H929 cells were treated with HYD1 for 2 hrs
and placed in soft agar for 12 days after which cell colonies were counted.

MM cell adhesion to bone marrow stroma cells, HYD1 treatment did reduce the level of
resistance to melphalan in the bone marrow stroma co-culture model system. Upon
testing HYD1 in the co-culture model system, an unanticipated observation was that
HYD1 treatment induced cell death in suspension culture as a single agent. Furthermore,
MM cells were not resistant to HYD1 treatment in the presence of bone marrow stroma
cells.
Due to the finding that HYD1 induced equivalent cell death in MM cells as a
single agent the mechanism of action of HYD1 induced cell death in suspension cultures
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was investigated. MM cells were treated with 12.5 or 50 µg/ml of HYD1, or the
scrambled peptide control HYDS, for 6 hours followed by measurement of annexin V
positive cells, used as a marker for cell death. HYD1 treatment increased annexin V
positive cell staining compared to cells treated with the scrambled variant HYDS in
H929, 8226 and U266 cells. HYD1 also inhibited in a dose dependent manner the ability
of H929 cells to form colonies in soft agar (figure 4).
In order to examine if HYD1-induced cell death was dependent on the apoptotic
pathway involving caspases, the processing and activation of caspases was examined. 6
hours treatment with 50 µg/ml of HYD1 did not result in the activation of caspase-8 and
only a minimal activation of caspase-3. Also, HYD1 treatment did not give rise to
cleaved active form of caspase−3, −9 and −8 as shown by western blot analysis in H929
and 8226 cells (figure 5). It was next determined if HYD1 induced a latent induction of
caspases. The pan caspase inhibitor zVAD-fmk was utilized to determine whether
caspases contributed to HYD1 induced cell death following 24 hours of HYD1 treatment.
Pretreatment of H929 cells with zVAD-fmk did not inhibit cell death induced by HYD1.
In contrast, zVAD-fmk treatment blocked the majority of the melphalan-treated annexin
V positive cells. These data were consistent with caspase activity assays which
demonstrated that neither caspase 3 or 8 activity was induced following 24 hours of
HYD1 treatment.
Endonuclease G (Endo G) and AIF have been reported to be released from the
mitochondria in caspase independent manner. After mitochondrial damage, the
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Figure 5: HYD1 did not induce apoptotic cell death. (A). H929 cells were treated
with the indicated concentrations of drugs for 6 hrs before activated caspase-3 and
caspase-8 were measured. (B). H929 cells were treated with 50 µg/ml of HYD1 and
HYD1s or 50 ng/ml of TRAIL for 6 hrs and cleaved caspases were measured by western
blot.

proapoptotic protein Bax is activated and functions in the formation of outer membrane
mitochondrial pore, causing the release of AIF and Endo G from the mitochondria. This
is followed by translocation of AIF and Endo G to the nucleus, leading to DNA
fragmentation and nuclear condensation [164]. HYD1 treatment failed to increase the
proportion of active Bax, as the levels were comparable to those seen in HYDS treated
and control cells. There was also no translocation of AIF or Endo G from the cytoplasm
to the nucleus after 6 hour treatment with HYD1. Finally, double-stranded DNA breaks
resulting from the internucleasomal DNA cleavage by endonucleases (mediated
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predominately by caspase activated DNAse, lysosomal DNAse II and Endo G) is an
important biochemical marker for apoptotic cell death [165].TRAIL treatment lead to a
significant increase in comet moments. However, HYD1, HYDS and control cells
showed equivalent comet moments indicating the absence of activation of endonucleases
and double stranded DNA breaks in HYD1 treated cells. Taken together, these data
demonstrate that HYD1-induced cell death occurs independent of caspase and
endonuclease activity. This data also indicates that HYD1 does not induce apoptosis in
MM cells.
Electron microscopy of HYD1 treated cells showed that 4 hours treatment with
HYD1 in H929 cells revealed the presence of several autophagosomes, observed as
extensive double-membrane vacuolar structure containing cytoplasmic contents. Such
autophagosomes were absent in HYDS treated cells. Another hallmark of autophagy is
the lipidation of LC3 protein, which can be detected by western blot analysis [166]. Thus,
western blot analysis was utilized to determine whether HYD1 treatment caused the
conversion of cytoplasmic form of LC3 (LC3-I, 18 k Da) to the autophagosomal
membrane-bound form of LC3 (LC3-II, 16 k Da). 4 hour treatment with HYD1 and
tunicamycin, a known inducer of autophagy, resulted in increased conversion of LC3-I to
LC3-II. HYD1 treatment also caused an increase in the number and size of acidic
vesicles as shown by lysosensor staining.
Depending on the context, the induction of autophagy has been shown to be associated
with cell survival or cell death. To determine whether autophagy induced by HYD1 plays
a role in cell survival or cell death, the autophagic pathway was inhibited by two
independent methods. siRNA targeting Beclin1, whose expression is required for the
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formation of pre-autophagosomal structures, was used as well as a pharmacological
approach using 3-methyladenine (3-MA), a nucleotide derivative and class III PI-3 kinase
inhibitor shown to inhibit the earliest stages of autophagosome formation. Both strategies
significantly sensitized H929 cells to HYD1-induced cell death, indicating that autophagy
is an adaptive response and contributes to survival of MM cells following HYD1
treatment. There is a mutual crosstalk between autophagy and apoptosis. It has been
reported that certain stimuli can induce cells to undergo autophagic cell death, and upon
inhibition of autophagy, under the same stimuli the cells revert to apoptotic cell death
[167]. To determine whether the increase in cell death observed upon HYD1 treatment
under the inhibition of autophagy was due to a switch to apoptotic cell death, cells were
pretreated with 3-MA followed by HYD1 and then examined for cleaved caspase−3, −8
and −9 in cell lysates by western blot analysis. Neither 3-MA, HYD1 alone nor their
combination caused cleavage of caspases. These results suggest that the inhibition of
HYD1-induced autophagy does not sensitize MM cells to undergo caspase-dependent cell
death (figure 6).
Major bioenergetic markers associated with necrotic cell death are the loss of
mitochondrial membrane potential (∆ψm) accompanied by loss of total ATP and a rise in
ROS production in cells. It was determined that HYD1 (50 µg/ml) treatment caused a
significant loss of ∆ψm in H929 and 8226 cells and a 62% decrease in ATP levels.
Additionally, HYD1 treatment resulted in a significant increase in ROS production when
compared to control cells. All these events occurred rapidly during treatment with HYD1,
suggesting that in MM cells HYD1 induces cell death through the necrotic cell death
pathway.
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Figure 6: HYD1 induces autophagy which had a cytoprotective effect in MM cells.
(A) H929 cells were treated with either 50 µg/ml HYD1 or HYDS or 100 µM
tunicamycin for 4 hrs and then processed for electron microscopy or LC3-1 to LC3-II
conversion. (B) H929 cells where transfected with a pool of 4 siRNA, targeting Beclin1
(siBECLIN1) or a control off Target siRNA (siCONTROL) using electroporation. 72 hrs
post-transfection the cells where treated for 6 hrs with HYD1 (50 µg/ml) and cell death
was determined by FACS analysis. (C) H929 cells were pretreated with 3-MA (10 mM)
for 45 min before the addition of varying concentrations of HYD1. Cell death was
determined by FACS analysis of annexin V positive cells after 6 hours of treatment.
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ROS has been shown to be an important mediator involved in propagation and execution
of necrotic cell death (figure 7).
To investigate whether an increase in ROS is the cause of cell death in HYD1
treated cells, cells were pretreated with 10 mM N-acetyl-cysteine (NAC), a thiol
containing free radical scavenger. NAC partially protects H929 from HYD1 induced cell
death. At the highest HYD1 concentration, NAC protected cells from death by 32% in
H929 and U266 cells when compared to cells treated with HYD1 only. These data
indicate that ROS plays an important role in inducing necrotic cell death in HYD1 treated
MM cells.
As discussed earlier, mitochondria are considered the major organelle capable of
generating ROS within cells. In order to determine whether ROS was the cause or the
product of loss of ∆ψm, cells were pretreated with NAC followed by treatment with
HYD1. Loss in ∆ψm was not reversed by pretreatment with NAC, indicating that ROS
production lies downstream of disruption of ∆ψm.
Finally, oxidative stress has been shown to induce autophagy. In order to
investigate whether autophagy observed in HYD1-treated cells was due to the induction
of ROS, cells were pretreated with NAC followed by HYD1 treatment. HYD1 caused a
substantial increase in LC3-II formation when compared to control cells. The increase in
LC3-II was completely reversed by pretreating cells with NAC. Moreover, the addition of
NAC reversed basal levels of LC3-II, suggesting that autophagy is driven by endogenous
ROS levels in MM cells and may be a general mechanism whereby cancer cells can
tolerate high basal levels of ROS typically associated with transformation. Taken
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Figure 7: HYD1 induces necrotic cell death in MM cells. (A) H929 cells were treated
for 2 hrs with HYD1 (50 µg/ml). Following treatment cells were analyzed for loss of
∆ψm, loss of total cellular ATP and increase in ROS production. (B) H929 cells were
pretreated with NAC (10 mM) for 30 min followed by addition of varying concentrations
of HYD1 for 6 hrs followed by cell death analysis. (C) H929 cells were pretreated with
NAC (10 mM) for 30 min before addition of HYD1 (50 µg/ml) for an additional 4 hrs.
Following treatment cells were analyzed for loss in ∆ψm. (D) H929 cells (4 × 105
cells/ml) were pretreated with NAC (10 mM) for 30 min before the addition of HYD-1
(50 µg/ml) for an additional 4 hrs. Following treatment, the LC3-1 to LC3-II conversion
was monitored by western blot analysis.

together, these data show that HYD1 induces ROS downstream of disruption of
mitochondria membrane potential. Additionally HYD1 induction of ROS can
paradoxically contribute to both cell survival by inducing autophagy and cell death by
inducing necrosis in MM cells.
A colony forming assay was used to determine whether HYD1 induced cell death
in normal hematopoietic cells. HYD1 did not inhibit colony formation of normal CD34+
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cells. Six hours treatment with increasing concentration of HYD1 did not induce cell
death up to doses of 50 µg/ml in PBMC. Finally, the SCID-hu model was used to
determine whether HYD1 demonstrates anti-tumor activity in vivo. The SCID-hu model
consists of implanting human fetal bone into the mammary mouse fat pad of SCID mice.
Mice treated with HYD1 showed a modest but significant reduction in tumor burden
compared to control mice (figure 8). In these experiments no overt toxicity or weight loss
was noted in HYD1 treated animals. Based on these results further studies are warranted
to determine the upstream targets causative for HYD1 induced depolarization of the
mitochondria membrane potential.
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Figure 8: HYD1 displayed in vivo activity in the SCID-hu mouse model. Tumor
burden in the SCID-Hu model was measured by quantification of circulating kappa levels
using ELISA. On day 28 (before drug treatment) measurements were recorded for each
individual mouse and subsequent values obtained weekly are represented as a ratio of day
28 (day X/day28). HYD1 was administered i.p. at 8 mg/kg daily for 21 days (starting day
28th). n=5 for vehicle control (VC) and 4 for HYD1 treated mice (P<0.05, ANOVA).
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Figure 9: Proposed mechanism of HYD1 induced cell death. HYD1 induces
mitochondrial dysfunction and a subsequent increase in ROS. The increase in ROS leads
to the induction of autophagy which results in cell survival or the induction of necrotic
cell death.
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Chapter 7: Objectives
Even though MM is a treatable disease, it is still deemed to be incurable. Novel
therapeutics, such as bortezomib, thalidomide and lenalidomide, have been shown to
prolong intervals of progression free disease and patient survival, but MM patients
ultimately relapse. Because MM develops resistance to treatment strategies, researchers
have invested considerable amounts of effort into delineating the mechanisms by which
multiple myeloma cells develop resistance. One mechanism in which myeloma cells
develop resistance is via cell adhesion to bone marrow stroma cells and ECM proteins
which is mediated by β1 integrin. Our laboratory has previously investigating the effects
of blocking the integrin interaction with the ECM using a β1 inhibitory peptide (HYD1).
In addition to blocking the adhesion of MM cells to bound FN, HYD1 was also
unexpectedly shown to have a cytotoxic effect as a single agent in vitro and in vivo.
HYD1 induced cell death displayed the same hallmarks as programmed necrosis;
increased loss of mitochondrial membrane potential, ROS generation and ATP depletion.
The primary goal of this project was to further delineate the mechanism of action that
causes HYD1 induced cell death in myeloma cells. To further characterize the
mechanism of HYD1 induced cell death an isogenic HYD1 resistant variant (H929-60)
was developed. Gene expression profiling (GEP) was used as an unbiased approach to
identify changes that may contribute to HYD1 resistance during the development of
H929-60 cells. After analysis of the GEP data, expression of integrins was determined to
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be significantly changed in H929-60 cells. Expression of key genes that induce Ca2+
release from ER stores was also changed. H929-60 cells also showed decreased surface
expression of α4 and β1 integrin and displayed decreased adhesion to fibronectin. After
analysis of the preliminary data the following hypothesis was proposed:
HYD1 binds the α4β1 integrin receptor in MM cells and leads to Ca2+ mediated
necrotic cell death.
In order to refute or support this hypothesis, the following objectives were
formulated:
1. Determine if a loss of integrin expression is causative for resistance to HYD1
induced cell death.
2. Determine if changes in intracellular Ca2+ levels effect HYD1 induced cell
death.
3. Determine if blocking pathways that lead to cell survival, like autophagy,
potentiates HYD1 induced cell death ex vivo and in vivo.
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Chapter 8: Materials and Methods:

Cell Culture:
NCI-H929, RPMI-8226 and HS-5 cells were obtained from the American Type
Culture Collection (Rockfield, MD). 293FT cells were obtained from Invitrogen and
grown in Iscove’s DMEM (Cellgro, VA) supplemented with 10 % FBS. Normal bone
marrow aspirate was purchased from Lonza, Inc (Allentown, NJ).

Mesenchymal stroma

cells (MSC) were generated by plastic adherence of the bone marrow aspirate. MSC
were confirmed by CD105, Stro-1, CD29 and CD73 positivity and CD34, CD33 and
CD45 negativity (data not shown). MSCs were grown in MEMα/GlutaMAXTM
supplemented with 10% fetal bovine serum-qualified (FBS-Q) and 1% 100x penicillinstreptomycin-glutamine (Invitrogen). 5TGM1 myeloma cells were derived from murine
myeloma 5T33.
Chemical Reagents, Antibodies, and Peptides:
5-Chloromethylfluorescein diacetate was purchased from Invitrogen (Carlsbad
CA). Melphalan, bortezomib, and N-acetyl-L-cysteine were purchased from SigmaAldrich (St. Louis MO). Anti-α4 integrin (clone P4G9) antibody was purchased from
Abcam (San Francisco CA). Anti-CD29 (4B7R) antibody was purchased from Novus
Biologicals (Littleton, CO). FITC-conjugated anti-integrin β7 (FIB504) was purchased
from Biolegend (San Diego CA). HYD1 (kikmviswkg) was synthesized by Bachem (San
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Diego CA) and FAM conjugated HYD1 (FAM-kikmviswkg) were synthesized by Global
Peptides (Fort Collins, CO).
Selection of a Drug-resistant Cell Line:
A HYD1 resistant cell line was developed as tool for delineating determinants of
resistance and sensitivity to HYD1 induced cell death. NCI-H929 cells were exposed to
increasing concentrations of HYD1 for 24 weeks. From weeks 1-8, cells were exposed to
10 µg/ml of HYD1 once a week for 24 hours. From weeks 9-16, cells were exposed to
20 µg/ml of HYD1 once a week for 24 hours. From weeks 17-24, cells were exposed to
30 µg/ml of HYD1 once a week for 24 hours. After week 24, the cells were exposed and
maintained in media containing 60 µg/ml HYD1 and subsequently named H929-60 cells.
Cell Death Analysis:
After treatment with HYD1, cells were washed with PBS and incubated with 2
nM TO-PRO-3 iodide for 45 minutes. The cells were analyzed for fluorescence with the
use of a FACSCalibur instrument (BD Biosciences, San Jose, CA).
Measurement of ∆ψm:
After treatment, cells were incubated for 15 minutes with 15 nM of 3,3’dihexyloxacarbocyanine iodide (Invitrogen). Cells were washed and resuspended in
PBS, and the loss of mitochondrial membrane potential was measured using FACScan.
ATP Measurement:
Treated cells were lysed in radioimmunoprecipitation assay buffer (Millipore,
Billerica, MD), and ATP concentrations were measured using the ENLITEN ATP
bioluminescence detection kit per manufacturer’s instructions (Promega, Madison, WI).
Samples were later normalized to the protein content of the lysates.

64

Confocal Microscopy:
To assess whether (a) HYD1 bound the cell surface and (b) whether binding of
HYD1 was reduced in the resistant cell line FAM-HYD1 was used to image peptide
binding in the parental and resistant cell line by confocal microscopy. A 35 mm glass
bottom microwell dishes (Mattek cultureware, Ashland, MA) were plated with 10 µL
Cell-tak (BD biosciences) per manufacturer’s instructions. Media containing 1 µM Alexa
Fluor 594 wheat germ agglutinin (WGA) (Invitrogen) and 20 µM Hoechst 33342
(Invitrogen) was placed back in the plates and the samples were incubated for 30
minutes. After 30 minutes, the cells were washed and treated with media containing 6.25
µg/ml FAM conjugated HYD1 for 10 minutes. Samples were immediately viewed with a
Leica DMI6000 confocal microscope (Leica Microsystems, Germany). Gain, offset, and
pinhole setting were identical for all samples within the treatment group.
Gene Expression Profiling:
One hundred nanograms of total RNA was isolated by a RNeasy mini kit
(Qiagen) and served as the mRNA source for microarray analysis. The poly(A) RNA
was specifically converted to cDNA and then amplified and labeled with biotin using the
Ambion Message Amp Premier RNA Amplification Kit (Life Technologies, Grand
Island, NY) following the manufacturer’s protocol. Hybridization with the biotin-labeled
RNA, staining, and scanning of the chips followed the prescribed procedure outlined in
the Affymetrix technical manual. The oligonucleotide probe arrays used were the Human
Genome U133 Plus 2.0 Arrays. This array contains over 54,000 probe sets representing
over 47,000 transcripts that were designed from GenBank, dbEST, and RefSeq sequences

65

that were clustered based on builds 133 and 159 of the UniGene database. Each gene is
represented by a series of oligonucleotides that are identical to the sequence in the gene as
well as oligonucleotides that contain a homomeric (base transversion) mismatch at the
central base position of the oligomer, which is used to measure cross-hybridization.
Scanned output files were visually inspected for hybridization artifacts and then
analyzed using Affymetrix GeneChip Operating Software (GCOS) using the MAS 5.0
algorithm. Signal intensity was scaled to an average intensity of 500 prior to comparison
analysis. Using the default settings, the GCOS software identifies the increased and
decreased genes between any two samples with a statistical algorithm that assesses the
behavior of 11 different oligonucleotide probes designed to detect the same gene (3).
Probe sets that yielded a change p-value less than 0.002 were identified as changed
(increased or decreased) and those that yielded a p-value between 0.002 and 0.002667
were identified as marginally changed. A gene was identified as consistently changed if
it was identified as changed in all 3 replicate experiments performed by the software.
Surface Expression of Integrins:
To determine cell surface expression of integrins, cells were treated with a
primary antibody for 45 minutes on ice. Cells were then washed and treated with a FITC
conjugated secondary antibody for 45 minutes on ice. Cells were washed again and the
fluorescence analyzed using a FACScan (BD Biosciences).
Cell adhesion to ECM proteins and Stroma:
Cell adhesion assays were performed to determine whether the resistant cell line
demonstrated reduced adhesive capacity. Briefly, cells were pre-incubated with various
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Figure 10: Hematopoietic cells can adhere to BMSCs and ECM proteins by various
receptors. For adhesion assays, MM cells were allowed to attach to FN, VCAM-1 or
HS-5 stromal cells for 2 hours. After 2 hours, unadhered cells were removed and cell
adhesion was read using a fluorescence plate reader.

antibodies for 30 minutes. Cells were then allowed to attach to 50 µL of 40 µg/mL FN
(Roche, Indianapolis, IN) or 10 µg/mL VCAM-1(Fisher Scientific, Pittsburgh, PA) for
two hours. After 2 hours, cell adhesion was detected by crystal violet staining as
previously described [168].
For stromal adhesion, 10,000 HS-5 or MSC cells were incubated overnight on
immunosorb 96 well plates (Nunc, Denmark). H929 and H929-60 cells were incubated
with 1uM of chloromethylfluorescein diacetate, or CMFDA (Invitrogen) for 30 minutes,
washed and incubated for 45 minutes to allow unbound dye to diffuse out of the cells.
Intensity was read on a fluorescence plate reader[169].
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Reverse transcriptase Polymerase Chain Reaction (Rt-PCR):
Rt-PCR was used to determine whether the decrease in α4 integrin protein levels
in the resistant cell line was due to decreased transcription. RNA was extracted from log
growth cells with RNeasy columns (Qiagen, Valencia, CA) per manufacturer’s
instructions. First–strand cDNA synthesis was carried out with the Quantitect Probe RTPCR kit (Qiagen, Valencia, Ca) per manufacturer’s instructions. Real time PCR primers
for alpha 4 integrin were obtained from Applied Biosystems (Carlsbad, Ca). The geneexpression level was normalized using the endogenous control gene GAPDH. Real-time
PCR reactions were performed using ABI 7900 Sequence Detection System (Applied
Biosystems).
Transfection of shRNAs:
ShRNA targeting strategies were used to determine whether α4 integrin
expression was causally related to HYD1 induced cell death. α4 (TRCN0000029656)
and β1 (TRCN0000029645) shRNA and non-silencing clone sets were purchased from
Open Biosystems, Huntsville, AL and transfected into a lentivirus using the BLOCK-IT
Lentiviral Pol II miR RNAi expression system (Invitrogen). After the viral supernatant
was collected, 500,000 myeloma cells were infected with a 250 µL viral supernatant/750
µL media solution and 5 µg/mL polybrene (Sigma) for 24 hours. After 24 hours, the
solution was removed and replaced with fresh media. At 72 hours of infection, 1µg/mL
puromycin (Invitrogen) was added to 8226 cells to allow for the selection of a stable
population of cells. For the H929 cell line, transient infections were used to reduce
integrin expression.
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Figure 11: The coculture model is used to determine EM-DR of MM cells in the
presence of stromal cells. MM cells are incubated in the presence or absence of HS-5
GFP stromal cells for 24 hours. After 24 hours, cells are treated with melphalan or
bortezomib for 24 hours. After treatment, MM cells are unattached to stromal cells using
Cellstripper and cell death is measured using a FACSCalibur instrument

Biotin-HYD1 pull-down assay:
To identify HYD1 interacting proteins biotin conjugated HYD1 was used as bait
as previously described [170]. Briefly, 100 million H929 or the resistant variant H929-60
were washed once in PBS and then in alkaline phosphatase (ALP) buffer. Samples were
spun at 15000xg for minutes at 4 degrees and the supernatant was removed and
membranes were pelleted at 100,000xg for 15 minutes. Membrane pellets were
solubilized in AP buffer containing 0.2% NP40 and protein was quantified using BCA
reagents (Pierce, Rockford, IL). Five hundred µg of Biotin-HYD1 was bound to 30 µL of
Ultra Link Neutral Avid in Plus beads (Pierce) for one hour in a buffer containing 0.5
mM Bcl, 0.3 mM KH2PO4, 27.6 mM Nail and 1,6 mM Na2HPO4, pH 7.4. After one
hour, the beads were washed twice in AP buffer and 50 µg of membrane extracts were
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added to a total volume of 500 µL and incubated with beads overnight at 4 degrees. The
beads were washed five times in AP buffer containing 0.2% NP40 and samples were
suspended in SDS-PAGE sample buffer and bound proteins were resolved by SDSPAGE.
Isolation of CD138 positive and negative populations derived from MM specimens:
To determine whether HYD1 was active in primary patient specimens 7 newly
diagnosed and 7 relapsed specimens were obtained. Myeloma patients were consented
through the Total Cancer Care tissue banking protocol per IRB regulations. Mononuclear
cells were separated from human blood through the use of Ficoll-Paque PLUS (GE
Healthcare, UK). After separation, CD 138 positive cells were sorted using 25 MS
MACS Separation Columns (Miltenyi Biotec, Germany) and CD 138 microbeads
(Miltenyi) per manufacturer’s instructions. For each specimen obtained α4 integrin
surface expression was determined by FACS analysis and HYD1 induced cell death was
determined by Topro-3 staining and FACS analysis in the CD138 positive and negative
fraction.
Measurement of Intracellular Ca2+Concentrations:
Intracellular free-calcium was measured using the Ca2+ sensitive dye, fura-2. 35
mm glass bottom microwell dishes (Mattek cultureware, Ashland, MA) were plated with
10 µL Cell-tak (BD biosciences) per manufacture’s instructions. Fura-2 loading was
carried out incubating the plated cells for 1 hour at room temperature in either
physiological saline solution (PSS) consisting of (in mM): 140 NaCl, 3 KCl, 2.5 CaCl2,
1.2 MgCl2, 7.7 glucose and 10 HEPES (pH to 7.2 with NaOH), which also contained 1
µM of the membrane permeable ester form of fura-2, acetoxymethylester (fura-2 AM)
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and 0.1% dimethyl sulfoxide (DMSO) or in PSS which did not contain CaCl2. All drugs
were bath applied in PSS.
A DG-4 high speed wavelength switcher (Sutter Instruments Co., Novato, CA)
was used to apply alternating excitation with 340- and 380-nm UV light. Fluorescent
emission at 510 nm was captured using a Sensicam digital CCD camera (Cooke Corp.,
Auburn Hills, MI) and recorded with Slidebook Version 3.0 software (Intelligent Imaging
Innovations, Denver, CO). Changes in [Ca2+]i were calculated using the Slidebook 3
software (Intelligent Imaging Innovations, Denver, CO) from the intensity of the emitted
fluorescence following excitation with 340- and 380-nm light, respectively, using the
equation,

where R represents the fluorescence

intensity ratio (F340/F380) as determined during experiments, Q is the ratio of Fmin to Fmax
at 380 nm, and Kd is the Ca2+ dissociation constant for fura-2. Calibration of the system
was performed using a fura-2 calcium imaging calibration kit (Molecular Probes, Inc.,
Eugene, OR) and values were determined to be as follows: Fmin/Fmax = 23.04; Rmin =
0.31; Rmax = 8.87.
Murine 5TGM1 Myeloma Model:
Animal studies were conducted using 6- to 8-week-old female
C57BL/KaLwRijHsd mice (Harlan) in accordance with the NIH Guide for the Care and
Use of Laboratory Animals. C57BL/KaLwRijHsd mice are used as the murine MM cell
line 5TGM1 was established from these mice. 5TGM1 cells were induced in mice by i.v.
inoculation through tail veins. Establishment of myeloma tumor in inoculated mice was
followed by assaying immunoglobulin G2b (IgG2b) monoclonal paraprotein in sera
prepared from whole blood obtained by sub-mandibular bleed. Mouse IgG2b levels were
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assayed by ELISA (Bethyl Laboratories, Montgomery, Texas) on days 7,14,21, and 28
per manufacturer’s instructions.
On day 10 after inoculation, the mice are treated with indicated doses of
treatment: 10 mg/kg and 25 mg/kg for cHYD1, 0.5 mg/kg for bortezomib, and 10 mg/kg
for chloroquine. Mice are treated 3 times weekly on Monday, Wednesday and Friday for
21 days for a total of nine treatments. For the chloroquine studies, mice were treated with
10 mg/kg chloroquine on days 9, 16, and 23 while mice were treated with 10 mg/kg HM27 on days 10, 13, 15, 17, 20, 22, 24, 27 and 29.Following treatment, mice are examined
until they need to be euthanized. Euthanization occurs when mice display hind leg
paralysis or tumors grow in excess of 2 cm in diameter. On day 100, all remaining mice
are euthanized.
Statistical Analysis:
For microarray data using the Mas 5.0 platform, significant genes were
determined by comparing changes in expression across 3 individual experiments. If
expression levels were increased across all 3 experiments or decreased in each
experiment the gene was deemed to be significant. For microarray data using RMA,
genes that were increased or decreased 2 fold between the two cells lines were
determined to be significant. For all other experiments, either a student’s t-test or
analysis of variance (ANOVA) test were used as indicated by each figure legend.
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Chapter 9: Results
H929-60 cells are resistant to HYD1 induced cell death but do not show crossresistance to other active myeloma agents:
To identify determinants of resistance towards HYD1, we developed an isogenic
resistant H929 cell line variant by chronically exposing H929 cells to increasing
concentrations of HYD1 until a drug resistant variant emerged. As shown in figure 10,
the H929-60 cell line is significantly resistant to HYD1 induced cell death (p<0.05
ANOVA) when compared to the parental H929 cells as measured by TOP-RO 3
positivity and FACS analysis. HYD1 induced cell death was previously characterized by
the loss of mitochondrial membrane potential, ATP depletion, and an increase in reactive
oxygen species (ROS). To determine whether the acquisition of resistance occurred
upstream or downstream of mitochondria dysfunction the mitochondria membrane
potential, ATP levels and ROS levels were compared following HYD1 treatment in the
resistant (H929-60) and sensitive parental cell line (H929). H929-60 cells were shown
to be resistant to the loss of mitochondrial membrane potential (figure 11) and failed to
show a reduction in ATP levels following HYD1 treatment (figure 12). Finally ROS
levels were reduced following HYD1 treatment in the resistant cell line compared to the
parental cell line (figure 13). We utilized a FAM conjugated HYD1 peptide to determine
whether the H929 resistant variant demonstrated a reduction in binding of FAM-HYD1 to

73

Figure 12: H929-60 cells are resistant to HYD1 induced cell death. H929 and H92960 cells were incubated with varying concentrations of HYD1 for 6 hours and HYD1
induced cell death was determined by Topro-3 staining and FACS analysis (ANOVA test
p<0.05 n=9). The experiment was repeated 3 independent times and a representative
experiment is shown.

the cell membrane As shown in figure 14, FAM-HYD1 localizes to the plasma membrane
in the parental cell line. Furthermore, the localization of FAM-HYD1 was not evenly
distributed across the cell membrane, but rather FAM-HYD1 demonstrated punctuated
staining in the parental cell line, suggesting potential clustering of the binding target.
H929-60 cells treated with 6.25 µg/ml FAM-HYD1 demonstrated a 2.7-fold reduction in
FAM-HYD1 binding relative to the parental cell line as determined by FACS analysis
(data not shown). Collectively, these data indicate that the mechanism causative for
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Figure 13: H929-60 cells display decreased HYD1 induced mitochondrial
dysfunction. Loss of mitochondrial membrane permeability was determined using
DiOC6 staining following 2 hours of HYD1 treatment in H929 and H929-60 (* denotes
p<0.05 n=9, Student’s t-test). The experiment was repeated 3 independent times and
shown is a representative experiment.

resistance towards HYD1 occurs upstream of mitochondrial dysfunction and generation
of ROS and that the resistant mechanism is likely the result of qualitative or quantitative
changes in the HYD1 binding complex located on the cell membrane.
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Figure 14: H929-60 cells do not display HYD1 induced ATP depletion. ATP levels
were determined in the H929 and H929-60 cell lines following 6 hours of HYD1 (50
ug/ml) treatment. (* denotes p<0.05 and # denotes p>0.05, n=9, Student’s t-test). The
experiment was repeated 3 independent times and shown is a representative experiment.
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Figure 15: HYD1 induced levels of ROS are decreased in H929-60 cells compared to
H929 cells. ROS production was measured using the dye 5-(and-6)-carboxy-2’,7’dichlorodihydro-fluorescein diacetate. H929 and H929-60 cells (4 × 105 cells/ml) were
treated for various time points (0, 30, 60 and 120 minutes) with 50 µg/ml HYD1 or
VC(H20). Dye fluorescence intensity was analyzed using Wallac VICTOR2 1420
multilabel counter (EG&G Wallac, Turku, Finland) (excitation: 485 nm, emission: 535
nm). A representative of three independent experiments is shown.
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Figure 16: H929-60 cells demonstrated reduced binding of FAM-HYD1 to the cell
surface. H929 and H929-60 cells were stained with Alexa Fluor 594 wheat germ
agglutinin (WGA) and Hoechst 33342 for 30 minutes. 6.25 µg/ml FAM-HYD1 was
added 10 minutes prior to analysis by confocal microscopy. The experiment was
repeated 3 independent times and shown is a representative experiment.
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Table 1: H929-60 cells are not resistant to standard myeloma therapies.
Compound

H929 cells

IC50 (n=3) H929-60 cells

melphalan

11.3 +/- 2.5 µM

13.1 +/- 3.7 µM

mitoxantrone

1.42 +/- .4 µM

1.05 +/- .7 µM

bortezomib

11.3 +/- 5.1 nM

12.2 +/- 3.9 nM

IC50 (n=3)

H929 and H929-60 cells were treated with increasing concentrations of melphalan (100,
50, 25, 12.5, 6.25, 3.25 and 0 uM), mitoxantrone (8, 4, 2, 1, 0.5, 0.25, 0.125 and 0 uM)
and bortezomib (256, 128, 64, 32, 16, 8, 4 and 0 nM) for 24 hours. After 24 hours, cells
were stained with annexin V FITC/PI and acquired on FACScan. IC50 values were
determined by linear regressions. Comparisons between H929 and H929-60 were not
deemed to be significant using a students t-test (p>0.05 n=9).

Selection of acquired resistance in a population of cells (rather then clonal
selection) often leads to multiple mechanisms of resistance and a phenotype that confers
resistance to multiple agents [171]. However, we hypothesized that since HYD1 induces
necrotic cell death, selection with HYD1 would not result in a phenotype which conferred
resistance to other agents commonly used to treat myeloma. To address this question, we
compared the IC50 values of H929-60 and the parental H929 cells to the alkylating agent,
melphalan, the topoisomerase II inhibitor, mitoxantrone, and the proteasome inhibitor,
Bortezomib. As predicted, H929-60 cells were not resistant to other classes of agents
commonly used to treat multiple myeloma and known to induce apoptosis (Table 1).
These data further support the potential advantage of targeting necrosis in combination
with inducers of apoptosis for the treatment of multiple myeloma, as cross-resistance
between these two agents is unlikely to occur during the course of drug treatment.
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Expression of integrin genes are significantly changed in H929-60 cells when
compared to H929 cells.
Gene expression profiling (GEP) of H929 and H929-60 cells was utilized as an
unbiased way of analyzing expression of genes that are significantly changed between the
H929 and H929-60 cell lines. Scanned output files were visually inspected for
hybridization artifacts and then analyzed by Affymetrix Microarray Suite 5.0 and robust
multi-array average (RMA) software. 5700 genes were deemed to be significantly
changed when Mas 5.0 software was utilized. Significance was determined when gene
expression was increased or expression was decreased in all 3 of the samples tested.
While Mas 5.0 is good at predicting true fold change between comparison groups, it also
produces more false positive genes. In order to more precisely determine what genes
were changed, RMA software was also used to determine significance between groups.
2200 genes were deemed to be significantly changed when RMA software was utilized.
Significance was determined when there was more than a two fold difference in gene
expression between H929 and H929-60 cell lines. Each set of significantly changed
genes was put into the pathway analysis programs GeneGO and Ingenuity to determine
key pathways and gene families are significantly. As shown in table 2, the integrin
family of genes were significantly changed in H929-60 cells compared to H929 cells.
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Table 2: Genes expressing integrins were significantly changed in H929-60 cells
compared to H929 cells.
Fold change

Integrin

H929

H929-60

Adheres to

Alpha 1

absent

absent

Collagen

Alpha 2

absent

absent

Collagen

Alpha 3

166.3

135.5

-1.24

Laminin

Alpha 4

4367.6

5169.1

1.18

FN, VCAM1, MadCAM-1

Alpha 5

absent

absent

Alpha 6

530.5

99.5

-5.33 (*) #

Laminin

Alpha 7

80.1

191.9

2.40 (*)

Laminin

Alpha 8

2144.6

1791.4

-1.20

FN

Alpha L

580.6

4771

8.22 (*) #

ICAM 1-3

Alpha V

620.5

381.3

-1.63 (*) #

FN, VN

Beta 1

6713.6

6127.8

-1.39 (*)

Collagen, FN, Laminin, VN

Beta 3

absent

absent

Beta 5

1038.6

2387.0

2.30 (*) #

FN

Beta 7

15047.3

18940.8

1.26 (*)

MadCAM-1

Beta 8

169.3

28.2

-6.00 (*) #

VN

FN

FN, VN

Probe sets that express integrins were tested for significance between H929 and H929-60
cells. 8 out of 11 genes that were expressed in H929 and H929-60 cells were determined
to be significantly changed using Mas 5.0 software while 5 out of 11 genes were
significantly changed using RMA. Significance using Mas 5.0 was determined if
expression levels were either increased across 3 individual experiments or decreased
across 3 individual experiments. Significance using RMA was determined if there was a
2 fold difference in gene expression between H929 and H929-60 cells. (*=significance
using Mas 5.0, #=significance using RMA)
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Acquisition towards resistance to HYD1 results in reduced expression of α4, β1
integrin and ablated functional binding to FN and VCAM-1:
To determine whether the acquisition of resistance correlated with quantitative
changes in integrin expression we screened multiple α integrin sub-units (α3, α5, αV and
α6 integrin data not shown) that are commonly expressed in hematopoietic cells and
determined that α4 integrin was the most abundant integrin expressed on the parental cell
line and expression was reduced in the resistant cell line (figure 15). Using FACS
analysis we determined that α4 integrin was found to be reduced by 1.8 fold. As shown
in figure 16, the reduction at the cell surface corresponded to reduced protein expression
using a whole cell whole cell lysate preparation. Interestingly, when examining the
whole cell lysate the most dramatic decrease was the cleaved form of α4 integrin. In
some cell types, the mature 150 kD α4 integrin is cleaved into a non-disulfide linked 80
and 70 kD fragment. For example, activation of T-cells was previously reported to
correlate with increased cleavage of the mature α4 integrin[172]. However, the cleavage
of α4 integrin was found to not alter the adhesive properties of VLA-4 integrin to
fibronectin or VCAM1[173]. The attenuation of protein expression is posttranscriptionally regulated as the parental and resistant cell line demonstrated equal levels
of α4 mRNA (Figure 16). Further studies are warranted to delineate the posttranscriptional regulation of α4 integrins in the resistant cell line.
Since β1 integrins require inside-out activation in order to be competent to bind
ligand, expression does not necessarily directly correlate with functional adhesion. Thus,
we next sought to determine whether a reduction in the expression of VLA-4 integrin
resulted in a functional reduction in adhesion to extracellular matrices. To this end, we
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*
*

Figure 17: α4 and β1 integrin surface expression are reduced in H929-60 cells.
Surface expression of α4 and β1 integrin on H929 and H929-60 cells was determined by
FACS analysis (* denotes p<0.05 n=9, Student’s t-test). A representative of each
experiment is shown.

compared the levels of adhesion of the sensitive and resistant cell line to fibronectin and
the more specific ligand for α4 integrin, VCAM-1. In figure 17, H929-60 cells
demonstrated a dramatic reduction in the binding to FN and VCAM-1. An α4 integrin
blocking antibody was used as a positive control for blocking the parental cell line to FN
and VCAM-1.
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Figure 18: H929-60 cells have decreased α4 integrin protein but not mRNA levels.
Whole cell lysates of H929 and H929-60 cells were probed for α4 integrin, β1 integrin
and beta actin by Western blot analysis. α4 integrin mRNA levels were determined using
real time rt-PCR. α4 integrin mRNA expression levels were normalized by dividing by
GAPDH levels (p>0.05 n=3). A representative of each experiment is shown.
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H929

H929-60

B)
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*

#

H929

H929-60

Figure 19: H929-60 cells have reduced α4 integrin protein levels and reduced
adhesion to FN and VCAM-1. H929 and H929-60 cells were incubated with α4
blocking antibody or IgG control antibody for 30 minutes and subsequently adhered to
(A) FN (40 µg/ml) or (B) VCAM-1 (10 µg/ml) coated plates for 2 hours. A
representative of each experiment is shown (* denotes p<0.05 or # denotes p>0.05
Student’s t-test).
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Reducing the expression α4 and β1 integrins causes resistance to HYD1 induced cell
death in H929 and 8226 MM cells.
Considering H929-60 cells were resistant to HYD1 induced cell death and
demonstrate reduced surface expression of the α4 integrin subunit, we next determined
whether reducing the expression of α4 integrins using shRNA targeting strategies in
myeloma cell lines was sufficient to induce resistance towards HYD1 induced cell death.
As shown in figure 18, reducing the expression of α4 integrin conferred resistance to
HYD1 (p<0.05, Student’s t-test) in both 8226 and H929 cells.
Since α4 integrin can heterodimerize with either β1 or β7 integrin, we tested
whether reducing β1 integrin was sufficient to induce resistance to myeloma cell lines.
As shown in figure 19, reducing β1 integrins rendered H929 and 8226 cells resistant to
HYD1 induced cell death (p<0.05, student’s t-test). β1 integrin can heterodimerize with
11 different α sub-units. The observation that reducing α4 or β1 integrin gave similar
levels of protection indicates that the α4β1 integrin is the predominant β1 integrin partner
associated with HYD1 induced cell death in myeloma cells. The observation that
reducing integrin expression afforded only partial resistance may be due to (a) residual
levels of α4β1 integrin remaining on the cell surface or (b) α4β1 represents only one
component of the binding complex required for HYD1 induced cell death.
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Figure 20: Reducing the expression of α4 integrin caused partial resistance to
HYD1 induced cell death in H929 and 8226 cells. A) In H929 cells α4 integrin
expression was reduced via transient infection. A: At 72 hours post infection of shRNA,
α4 integrin expression was determined by FACS analysis. 8226 cells were stably infected
with α4 integrin shRNA or control vector shRNA. Shown is a representative histogram
from one experiment. B) H929 and 8226 cells were treated with 50 µg/ml and 100ug/ml
of HYD1 respectively for 6 hours. After 6 hours, cell death was analyzed by Topro-3
staining and FACS analysis. (* denotes p<0.05 n=9, Student’s t-test).
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Figure 21: Reducing the expression of β1 integrin caused partial resistance to
HYD1 induced cell death in H929 and 8226 cells. A) In H929 cells β1 integrin
expression was reduced via transient infection. A) At 72 hours post infection of shRNA,
β1 integrin expression was determined by FACS analysis. 8226 cells were stably infected
with β1 integrin shRNA or control vector shRNA. Shown is a representative histogram
from one experiment. B) H929 and 8226 cells were treated with 50 µg/ml and 100ug/ml
of HYD1 respectively for 6 hours. After 6 hours, cell death was analyzed by Topro-3
staining and FACS analysis. (* denotes p<0.05 n=9, Student’s t-test).
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Biotin-HYD1 interacts with α4 integrin and reduced binding was observed in the
cell line with acquired drug resistance.
Previous data indicated that biotin-HYD1 associated with α3 and α6 integrins but
not α2 integrins on prostate cancer cell lines[170]. We utilized a similar strategy to
determine whether biotin-HYD1 interacted with an α4 integrin containing complex and
whether that interaction was attenuated in the resistant cell line. The total membrane
lysate was used as a control for detection of α4 integrin. Again the reduction in the
cleaved α4 integrin subunit in membrane extracts (although not as dramatic as the whole
cell lysate), was most prominent in the resistant cell line compared to the mature α4
integrin subunit. Additionally, as shown in Figure 20, using biotin-HYD1 we
demonstrate that the resistant cell line shows decreased binding for the cleaved α4 subunit. Further studies are warranted to fully understand the significance of the cleaved α4
integrin sub-unit in mediating HYD1 induced cell death and the CAM-DR phenotype.
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Figure 22: Biotin-HYD1 interacts with α4 integrin and binding to cleaved α4
integrin is attenuated in the resistant H929-60 cells. H929 and H929-60 membrane
fractions were added to biotin or biotin-HYD1 bound NeutrAvidin beads for 18 hours as
described in the methods and materials section. The experiment was repeated twice and a
representative experiment is shown.

H929-60 cells displayed reduced binding to bone marrow stromal cells and
demonstrate a compromised CAM-DR phenotype.
In addition to attenuated adhesion to FN and VCAM-1, H929-60 cells also exhibit
a reduction in adhesion to the HS-5 stromal cell line and mesenchymal stroma cells
(MSC) (Figure 21). We reasoned that acquisition of resistance towards HYD1, which
correlated with reduced functional binding to fibronectin, VCAM-1, HS-5 stromal cells
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and MSC, would likely result in a compromised CAM-DR phenotype. To test this
premise, we utilized the HS-5 co-culture model of drug resistance. H929 and the HYD1
resistant variant H929-60 cells were treated with either melphalan or bortezomib in the
presence or absence of HS-5/GFP bone marrow stromal cells. As shown in Figure 22, the
HYD1 resistant cell line was not resistant in the co-culture bone marrow stromal model to
melphalan or bortezomib, respectively. There is some controversy in the literature
whether co-culturing myeloma cells with stroma cells causes resistance to
bortezomib[174]. The apparent discrepancy may be the result of endpoints that measure
growth compared to cell death, dose of bortezomib or the scheduling of how long
myeloma cells interact with the stroma before exposure. Additionally, exposure to
bortezomib for 24 hours was shown to downregulate α4 integrin levels and thus drug
scheduling could also impact observed results [96]. However, our results are consistent
with recent reports showing that myeloma cells are resistant to bortezomib in MSC coculture models. [175]. Together, these data indicate that as myeloma cells are selected
for resistance to HYD1 they are losing resistance to standard chemotherapy in the context
of the bone marrow microenvironment due to reduced capacity to adhere to bone marrow
stromal cells. Again these data support the premise that disrupting adhesive interactions
are likely to improve the efficacy of standard chemotherapy in the context of the bone
marrow microenvironment.
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Figure 23: H929-60 cells display reduced binding to HS-5 and MSCs.
A-B) H929 and H929-60 cells pre-incubated with CMFDA dye were adhered to 10,000
A) HS-5 cells or B) MSC cells for 2 hours. After 2 hours, unadhered cells were removed
and the fluorescence intensity was measured on a plate reader. A representative of three
independent experiments was shown. (* =p<0.05, n=9 Students t-test).
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Figure 24: H929-60 cells are not resistant to melphalan or bortezomib in the stroma
co culture model. A-B): H929 and H929-60 cells were adhered to HS-5 GFP cells for
24 hours. After 24 hours samples were treated with 15 µM melphalan or 16 nM
bortezomib for 24 hours. Cell death was analyzed using To-PRO 3 intensity on a
FACScalibur with the HS-5 GFP cells excluded from the analysis. A representative of
three independent experiments was shown. (* =p<0.05, n=9 or# =p>0.05, n=9 Students
t-test).
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HYD1 induced cell death is increased in relapsed myeloma patient specimens
compared to newly diagnosed specimens and correlates with α4 integrin expression.
In order to determine whether primary myeloma specimens are sensitive to HYD1
induced cell death, 7 newly diagnosed and 7 relapsed primary myeloma specimens were
collected. Immunomagnetic beads were used to enrich for CD138 positive malignant
plasma cell fractions. As shown in Figure 23A, the CD138 positive tumor population
was more sensitive to HYD1 induced cell death compared to the CD138 negative
population. In addition to measuring cell death, the levels of α4 integrin expression were
determined in the CD138 positive cells by FACS analysis. As shown in Figure 23B,
HYD1 induced cell death positively correlates with α4 integrin expression. Importantly,
HYD1 was observed to be significantly (p<0.05, student’s t-test) more active in relapsed
refractory patients compared to newly diagnosed patients (Figure 24A). Finally as shown
in Figure 24B, α4 integrin levels are increased in CD138 positive cells isolated from
relapsed myeloma patients compared to newly diagnosed patients (p<0.05, student’s ttest). Together, these data suggest that α4 integrin expression is selected for over the
course of drug treatment and may contribute to the eventual failure to therapeutically
manage multiple myeloma. Additionally, patients with high levels of α4 expression may
benefit from combination strategies that include targeting this specific integrin complex
such as Natalizumab[176] (humanized α4 antibody) or HYD1.
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A)

B)
R2=.0.76

Figure 25: HYD1 induced cell death in CD138+ patient samples correlates with
increased α4 integrin expression. A) CD138+ and CD138- cells were treated with 100
ug/ml HYD1 for 24 hours. After 24 hours cell death was measured by Topro-3 staining
and FACS analysis. (p<0.05, Student’s t-test) B) α4 integrin expression was compared to
HYD1 induced cell death using a Pearson’s correlation coefficient. The CD138+
population demonstrated a significant correlation between α4 integrin expression and
HYD1 induced cell death (p<0.05).
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A)

B)
A)

Figure 26: Relapsed specimens have increased HYD1 induced cell death and α4
integrin expression. A-B) Specimens were separated into two groups: newly diagnosed
or relapsed patients. In A), CD138+ cells were treated with100 ug/ml HYD1 for 24
hours. After 24 hours cell death was measured by Topro-3 staining and FACS analysis
(Student’s t-test p<0.05) In B) CD138+ cells were used to analyze for α4 integrin
expression by FACS analysis. (Student’s t-test p<0.05
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A cyclized form of the active region of HYD1, named HM-27, was developed in
order to increase bioavailability and activity in MM cells.
One limitation to using peptidomimetics is that they have low bioavailability as
they can be degraded by serum proteases. As almost all eukaryotic proteins are made up
of L-amino acids, HYD1 was developed as a D-amino acid to make it more resistant to
serum proteases. In addition to changing the chirality of the amino acids,
peptidomimetics can also be pegylated or cyclized as a way to increase bioavailability.
Before HYD1 was cyclized, the active region of HYD1 was determined by truncating the
N and C terminus and testing for activity. Previous studies showed that the sequence of
HYD1 necessary to support cell adhesion was kmvixw, the block to migration required
xkmviswxx and activation of ERK signaling required ikmviswxx, with the shortest
sequence active in all three assays being kmvisw [162]. As shown in figure 25, the
shortest sequence of HYD1 that was also shown to have activity in MM cells was mvisw.
By using alanine screens on the active region of HYD1 and constraining the sequence by
cyclizing it, many compounds were tested for their ability to induce MM cell death. One
compound tested was named HM-27 which contains the sequence Nleu-V-V-A-W. HM27 was shown to be 30 fold more active in MM cells when compared to HYD1 (figure
26). H929-60 cells were also resistant to HM-27 when compared to H929 cells,
indicating that HM-27 induces cell death in MM cells via the same mechanism of action
as HYD1 (figure 27).
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Figure 27: A cyclized variant of HYD1, HM-27, was developed using the active core
of HYD1. Using truncation studies, the minimum sequence of HYD1 which still
displays activity in MM cells is mvisw. Performing alanine substitutions on the active
core and cyclizing the sequence to constrain the peptide produced the peptidomimetic,
HM-27.
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Figure 28: HM-27 displays increased activity in H929 cells when compared to
HYD1. H929 cells were incubated with varying concentrations of HYD1 and HM-27 for
24 hours and drug induced cell death was determined by Topro-3 staining and FACS
analysis. The experiment was repeated 3 independent times and shown is a representative
experiment.
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Figure 29: H929-60 cells are resistant to HM-27 induced cell death. H929 and H92960 cells were incubated with varying concentrations of HYD1 and HM-27 for 6 hours
and drug induced cell death was determined by Topro-3 staining and FACS analysis. The
experiment was repeated 3 independent times and shown is a representative experiment.
(*= p<0.05, student’s t-test)
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HM-27 and HYD1 induce intracellular Ca2+ oscillations in MM cells.
Necrosis is predominantly described as an accidental or uncontrolled form of
cellular death and is characterized by the activation of key bioenergetic events. These
events that are usually implicated in necrosis are; increased mitochondrial dysfunction,
ATP depletion, depletion of intracellular NAD+, increased levels of intracellular Ca2+,
and increased generation of ROS. As was previously shown, HYD1 induced cell death in
MM cells by depleting ATP, inducing loss of the mitochondria membrane potential and
generation of ROS. HYD1 was also shown to deplete intracellular NAD+ levels in MM
cells (data not shown). Levels of intracellular Ca2+ are also an important in mediating
necrotic cell death. If the concentration of intracellular Ca2+ is at too high a level
(>1µM), the mitochondria can become overloaded with Ca2+, leading to the opening of
the mPT pore and ATP depletion, which in turn leads to necrosis [130]. In order to test if
HYD1 treatment induced an increase in intracellular Ca2+, H929 and H929-60 cells were
incubated with Fura-2 dye and time lapse images were taken for either 60 minutes after
treatment with HYD1 or 30 minutes for HM-27. Both HYD1 (75 µM) and HM-27 (3
µM) were shown to elevate levels of intracellular Ca2+ in H929 and H929-60 cells.
HYD1 and HM-27 induced intracellular Ca2+ oscillations were also reduced in H929-60
cells when compared to H929 cells (figure 28). Individual H929 cells were examined to
determine if there were differences between the total levels or temporal differences in
Ca2+ levels after HYD1 or HM-27 treatment. As seen in figure 29, Ca2+ levels were
increased and occur earlier (10 minutes) after treated with HM-27 when compared to
HYD1 (30 minutes). These data suggest that HM-27 is more efficient in eliciting a Ca2+
response in MM cells when compared to HYD1.
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Figure 30: Intracellular Ca2+ levels are increased after treatment with HYD1 and
HM-27. H929 and H929-60 cells were adhered to cell-tak coated plates for 15 minutes
and then incubated with Fura-2 dye for 30 minutes. Time lapse images were taken for
either 60 minutes after treatment with 75 µM HYD1 or 30 minutes after treatment with 3
µM HM-27. A representative of three independent experiments was shown. (* =p<0.05,
Students t-test).
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Figure 31: There were differences in total levels of Ca2+ and differences in the time
needed to induce a Ca2+ response after treatment with HYD1 and HM-27. H929 and
H929-60 cells were adhered to cell-tak coated plates and were incubated with Fura-2 dye
for 30 minutes. Time lapse images were taken for either 60 minutes after treatment with
75 µM HYD1 or 30 minutes after treatment with 3 µM HM-27. A representative cell
closest to the median Ca2+ response of the whole population was shown.
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HM-27 induced increases in intracellular Ca2+ are a result of release from ER stores
and blocking this release resulted in increased HM-27 induced cell death.
Increases in intracellular Ca2+ occur either by influx via plasma membrane
channels or by release from internal stores in the ER or mitochondria. In order to
determine the source of HM-27 induced intracellular Ca2+ oscillations, H929 cells were
pretreated with the PLC inhibitor, U73122, in order to block Ca2+ release from the ER or
placed in a PSS buffer that did not contain CaCl2 in order to block Ca2+ influx through
plasma membrane channels. As shown in figures 30 and 31, inhibiting Ca2+ influx
through plasma membrane channels by depleting extracellular Ca2+ stores did not
decrease the levels of Ca2+ induced by HM-27 treatment. However, blocking the release
of Ca2+ from ER stores using U73122 decreased HYD1 induced Ca2+ oscillations. In
addition, inhibiting both the release of Ca2+ from ER stores and Ca2+ influx through
plasma membrane channels completely blocked the HM-27 induced Ca2+ response. These
data suggest that the increase in intracellular Ca2+ seen after treatment with HM-27 were
a result of the release of Ca2+ from ER stores and not from influx via plasma membrane
channels.
Next, it was determined if blocking the release of Ca2+ from ER stores would
inhibit HM-27 induced cell death. Instead of inhibiting HM-27 induced cell death,
pretreating with U73122 actually increased cell death (figure 32A). Next it was
determined if there was a relationship between HYD1 induced Ca2+ oscillations and
induction of autophagy. Previous reports have shown that beclin 1 and the ip3 receptor
form a complex along with Bcl-2 on the ER membrane and disrupting this

104

A)
VC
HM-27
U73122
HM-27/U73122

250 nM
5 minutes

Calcium

B)
VC
HM-27
U73122
HM-27/U73122

250 nM
5 minutes

No Calcium

Figure 32. HYD1 induced Ca2+ oscillations occur via release from ER stores. H929
cells were adhered to cell-tak coated plates and then incubated with Fura-2 dye +/U73122 for 30 minutes in PSS containing Ca2+ and PSS without Ca2+. Time lapse images
were taken for 30 minutes after treatment with 3 µM HM-27. A representative cell
closest to the median Ca2+ response of the whole population was shown.
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Figure 33. HYD1 induced Ca2+ oscillations occur via release from ER stores. H929
cells were adhered to cell-tak coated plates and then incubated with Fura-2 dye +/U73122 for 30 minutes in PSS containing Ca2+ and PSS without Ca2+. Time lapse images
were taken for 30 minutes after treatment with 3 µM HM-27. A representative
experiment is shown.

complex initiates the formation of autophagic vesicles. In order to determine if Ca2+
release from the ER causes an induction in autophagy, nucleoporin p62 degradation after
HM-27 treatment was analyzed. As seen in figure 32B, HM-27 induced p62 degradation
in H929 cells, indicating that HM-27 induced autophagy. Cells pretreated with U73122
partially blocked the degradation of p62, indicating that Ca2+ released from the ER causes
the induction of autophagy seen after HM-27 treatment. As inhibiting autophagy or Ca2+
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Figure 34. Inhibiting Ca2+ release from ER stores led to increased HM-27 induced
cell death and blocked HM-27 induced autophagy. A) H929 were pretreated with 2
µM U73122 and treated with 3 µM HM-27 for 2 hours in PSS +/- Ca2+. Drug induced cell
death was determined by Topro-3 staining and FACS analysis. B) H929 were pretreated
with 2 µM U73122 and treated with 3 µM HM-27 for 4 hours. Whole cell lysates of
H929 cells were probed for p62 and beta actin by Western blot analysis. The experiments
were repeated 3 independent times and shown is a representative experiment. (*= p<0.05,
student’s t-test
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Figure 35. There is increased HM-27 induced cell death in MM cells pretreated
with chloroquine when compared to cells pretreated with U73122. A) H929 and B)
8226 cells were pretreated with either U73122 or chloroquine for 30 minutes. Cells were
then treated with 3 µM HM-27 for 2 hours. Drug induced cell death was determined by
Topro-3 staining and FACS analysis. The experiments were repeated 3 independent times
and shown is a representative experiment. (*= p<0.05, #=p>0.05, student’s t-test)

release from the ER have both been shown to increase cell death after treatment with
HM-27, H929 and U266 cells were pretreated with either the lysosomotropic agent
chloroquine, which neutralizes lysosomal vesicles, or the plc inhibitor U73122 followed
108

by treatment with HM-27. As seen in figure 33 A and B, there was increased HM-27
induced cell death in MM cells pretreated with chloroquine when compared to cells
pretreated with U73122. While more studies are needed to delineate the mechanism of
how Ca2+ regulates autophagy after HM-27 treatment, these data do suggest that HM-27
cell death can be enhanced in vitro by inhibiting autophagy or Ca2+ release from the ER.
HM-27 induced cell death is increased in relapsed myeloma patient specimens with
chloroquine pretreatment potentiating this effect.
In order to determine whether primary myeloma specimens are sensitive to HM27 induced cell death, 6 newly diagnosed and 6 relapsed myeloma specimens were
collected. Immunomagnetic beads were used to enrich for CD138 positive malignant
plasma cell fractions. HM-27, like HYD1, was significantly more active in relapsed
refractory patients compared to newly diagnosed patients. Patient samples were also
treated with chloroquine to see if inhibiting autophagy would enhance HM-27 induced
cell death ex vivo. As seen in figure 34, pretreatment with chloroquine potentiated HM27 induced cell death in relapsed patient specimens but did not have any activity in newly
diagnosed patients. Together, these data suggest that HM-27 like HYD1 has increased
activity in relapsed patient samples compared to newly diagnosed specimens and
pretreatment with agents that inhibit autophagy enhance HM-27 induced cell death ex
vivo.
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Figure 36. HM-27 induced cell death is increased in relapsed myeloma patient
specimens with chloroquine pretreatment potentiating this effect. Specimens were
separated into two groups depending on the clinical diagnosis; either A) newly
diagnosed or B) relapsed patients. CD138+ cells were pretreated with 20 µM of
chloroquine for 30 minutes followed by 6 µM of HM-27 for 24 hours. After 24 hours cell
death was measured by Topro-3 staining and FACS analysis (Student’s t-test * =
p<0.05, # = p>0.05).
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HM-27 has antitumor activity in an in vivo model.
C57BL/KaLwRijHsd mice were used to determine if HM-27 demonstrates antitumor activity in vivo. 6- to 8- week old mice were injected with 5TGM1 cells via their
tail vein. At day 10 after injection, mice were treated with either 10 mg/kg HM-27, 25
mg/kg HM-27 or 0.5 mg/kg bortezomib. Mice were treated with drug 3 times a week for
3 weeks. An enzyme-linked immunosorbent assay (ELISA) was used to measure tumor
burden by measuring IgG2B levels in serum each week for 4 weeks. On day 27, control
mice had increased IgG2B levels when compared to drug treated mice with mice
expressing levels over 1 mg/ml exhibiting hind leg paralysis (figure 35A). Survival was
determined with mice being euthanized if they exhibited hind leg paralysis, an extended
abdomen or the presence of a tumor over 2 cm in diameter or reached 100 days post
inoculation. As seen in figure 35B, mice treated with 10 mg/kg of HM-27, 25 mg/kg
HM-27 or 0.5 mg/kg of bortezomib displayed increased survival when compared to
control mice. Since pretreatment with chloroquine potentiated HM-27 induced cell death
in vitro and ex vivo, mice were treated with chloroquine and HM-27 to determine if there
is increased in vivo activity when the drugs were given in combination compared to each
drug alone. Mice were treated with 10 mg/kg chloroquine on days 9, 16, and 23 while
mice were treated with 10 mg/kg HM-27 on days 10, 13, 15, 17, 20, 22, 24, 27 and 29.
ELISA data indicated that there was increased tumor burden in control cells compared to
cells treated with HM-27, chloroquine and combination treatment (figure 36A).
However, there was no added survival benefit when chloroquine and HM-27 were
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Figure 37: HM-27 has increased antitumor activity as a single agent in vivo.
A) IgG2B serum levels were measured by ELISA once a week for 4 weeks per the
manufacturer’s instructions. B) 1x106 5TGM1 cells were injected into 6-8 week old
C57BL/KaLwRijHsd mice via tail vein. At day 10, mice were treated with agents 3
times a week for 3 weeks. Mice were monitored daily for survival with all remaining
mice euthanized at day 100 after treatment
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Figure 38: Combination treatment with HM-27 and chloroquine does not increases
cell survival in vivo. . A) IgG2B serum levels were measured by ELISA once a week
for 4 weeks per the manufacturer’s instructions. B) 1x106 5TGM1 cells were injected
into 6-8 week old C57BL/KaLwRijHsd mice via tail vein. Mice were treated with 10
mg/kg of chloroquine on days 9, 16, and 23. At day 10, mice were treated with 10 mg/kg
of HM-27 3 times a week for 3 weeks. Mice were monitored daily for survival with all
remaining mice euthanized at day 100 after treatment.
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combined compared to chloroquine or HM-27 as a single agent (figure 36B).
Combination studies were also done with bortezomib and HM-27 to determine if there is
increased in vivo activity when the drugs were given in combination compared to each
drug alone. Mice were treated with 0.5 mg/kg of bortezomib or 10 mg/kg HM-27 3 times
a week for 3 weeks starting on day 10. ELISA data indicated that there was increased
tumor burden in control cells compared to cells treated with HM-27, bortezomib and
combination treatment (figure 37A). There also appears to be an increased survival in
mice treated with both agents compared to mice treated with a single agent (figure 37B)
These data indicate that HM-27, bortezomib and chloroquine each have in vivo activity as
a single agent. Combination therapy utilizing bortezomib and HM-27 appears to have
increased activity in vivo while combination therapy with chloroquine and HM-27 do not
appear to have increased activity. More studies are needed to determine if there are ways
to optimize the treatment schedule with chloroquine and HM-27 to see increased activity
in combination.
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Figure 39: Combination treatment with HM-27 and bortezomib increases survival
in vivo. A) IgG2B serum levels were measured by ELISA once a week for 4 weeks per
the manufacturer’s instructions. B) 1x106 5TGM1 cells were injected into 6-8 week old
C57BL/KaLwRijHsd mice via tail vein. At day 10, mice were treated with 10 mg/kg of
HM-27 and 0.5 mg/kg bortezomib 3 times a week for 3 weeks. Mice were monitored
daily for survival.
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Chapter 10: Discussion and Future Directions
Isogenic resistant cell lines have been used by many investigators as a model
system for delineating important molecular determinants of response for novel as well as
for developing and evaluating clinically approved agents [177-181]. Historically, some of
these cell line models have allowed for the identification of targets associated with drug
sensitivity and resistance[182]. Selection with HYD1 on H929 cells resulted in the
formation of the resistant cell line, H929-60. By analyzing gene expression profiling data
on both cell lines, it was determined that there were a significant number of integrin
genes changed when H929 cells were selected with HYD1. Interestingly, even though
H929-60 cells did not have reduced gene expression of α4 integrin, there was decreased
protein surface expression of α4 integrin. Quantitative RT-PCR expression of α4 integrin
validated the gene expression profiling data, indicating that the decrease in protein
expression in α4 integrin is due to a post transcriptional modification. There are ways in
which protein expression of α4 integrin are decreased even though gene expression was
similar. H929-60 cells could have decreased rates of translation when compared to H929
cells. There could also be increased rates of α4 integrin mediated endocytosis and
degradation by lysosomes or there could be increased rates of α4 integrin degradation by
the proteasome in H929-60 cells. Fluorescein labeled transferrin could be used to
determine if there is increased endocytosis in H929-60 cells. Blocking the proteasome in
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H929-60 cells can also be used to see if there is restoration of α4 integrin levels after
proteasome inhibition.
HYD1 was previously characterized as a β1 inhibitory peptide as it inhibited
adhesion to laminin by binding to α3 and α6 integrins. HYD1 was not shown to inhibit
the ability of the α6β4 integrin to adhere to laminin however. Therefore most of the
studies done on the HYD1 resistant cells focused on the α4β1 heterodimer. Using this
logic, we determined that knocking down surface expression of α4 and β1 integrins was
sufficient to decrease HYD1 induced cell death in MM cell lines. However, α4 integrin
has been shown to heterodimerize with either β1 integrin or β7 integrin. β7 integrin, like
α4 integrin, displayed no change in gene expression but exhibited decreased surface
protein expression in H929-60 cells. A previous study has shown that increased β7
integrin expression correlated with poor survival in MM cell lines and patient samples
[95]. More studies are needed to determine if HYD1 also targets the α4β7 heterodimer as
well as VLA-4. The surface expression of β7 integrins can also be knocked down as a
way to determine if the α4β7 heterodimer is also implicated in HYD1 induced cell death.
Previous data showed that HYD1 was able to block adhesion of MM cells to FN
after 2 hours but was not able to block adhesion of MM cells to HS-5 cells. However,
selection with HYD1 resulted in a cell line with compromised adhesive interactions
towards extracellular matrices and HS-5 bone marrow stroma cells and MSCs. Since
MM cell adhesion to stromal cells occurs by a multitude of receptors, it would be
interesting to determine if any of the other adhesion mediated receptors besides VLA-4
and α4β7 integrins are changed as cells are selected for HYD1 resistance. One
explanation could be that MM cells bind to stromal cells through both α4β1 and α4β7
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integrins but HYD1 is only able to target α4β1 integrin therefore not inhibiting the
adhesive capabilities of α4β7 integrin. However, as H929-60 cells are selected for
resistance, they lose surface expression of α4 integrins thereby downregulating both the
α4β1 and α4β7 heterodimers thereby decreasing adhesion to stromal cells. Another
explanation is that other receptors that mediate adhesion of MM cells to BMSCs are
downregulated. Subsequent studies have also shown that there is also decreased surface
protein expression of CD44 in the resistant cell line, which has been shown to mediate
MM adhesion to bone marrow stromal cells and contribute to CAM-DR [14].
Conversely, gene expression profiling data showed that there was an 8 fold increase in αL
integrin in H929-60 cells compared to H929 cells. Alpha L integrin dimerizes with β2
integrin to form LFA-1, a protein that adheres to ICAM receptors on BMSCs and has
been shown to contribute to CAM-DR [66]. It can be speculated that HYD1 resistant
cells compensate for decreased α4 integrin levels by upregulating the expression of other
proteins responsible for adhesion to stroma cells. Future studies would be aimed at
determining the surface expression levels of proteins such as LFA-1, notch-1 and CD138
which mediate adhesion to stromal cells and contribute to CAM-DR.
It was reasoned that a reduction in functional binding to the HS-5 bone marrow
stroma cell line may render the HYD1 resistant cell line sensitive to standard therapy in
the co-culture model of drug resistance. Indeed this was found to be true, as the HYD1
resistant cell line was not resistant to melphalan or bortezomib induced cell death in the
co-culture model of drug resistance. Moreover, it was demonstrated that α4 integrin
expression and sensitivity towards HYD1 was increased in specimens obtained from
relapsed patients compared to newly diagnosed patients, suggesting that α4 expression is
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selected either as a consequence of standard drug exposure or disease progression.
Previous studies have shown that α4 integrin is increased in relapsed patient samples,
when compared to newly diagnosed patients [93]. This observation in patient specimens
is also in agreement with acquisition of resistance towards melphalan and doxorubicin in
myeloma cell lines as expression of α4 integrin increased with selection for drug
resistance[69]. It is attractive to speculate that agents which disrupt cell adhesion may
indeed be a good strategy for compromising the overall fitness of cells in the context of
the BME. Agents that disrupt cell adhesion may be critical to test the development of
evolutionary based double bind strategies, where resistance to a drug is predicted to occur
at the cost of fitness within the niche. The utilization of double bind strategies is a unique
concept recently proposed by Gatenby and colleagues for delaying the emergence of
resistant variants in the treatment of cancer and indeed HYD1 may fit the criteria for an
agent to test this unique therapeutic strategy [183].
Our data indicate that reducing α4β1 integrin expression was sufficient to confer
partial drug resistance to HYD1. However, since only partial resistance was observed,
additional components contained within the HYD1 binding complex may contribute to
HYD1 induced cell death. An unbiased approach was used in order to determine other
surface proteins that are found in the complex with which HYD1 interacts. We incubated
membrane fractions with biotin conjugated HYD1 in order to identify other proteins that
bind to HYD1 by mass spectrometry. Other proteins that bound to biotin HYD1 besides
α4 integrin were CD44, CD147 and CD138. Previous studies have shown that CD44 and
VLA-4 interact on the surface of malignant B cells but not normal B cells [184]. CD147
has been shown to induce metalloproteinases as well as interact with CD44 on metastatic
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prostate cancer cells. CD138 also mediates MM cell adhesion to BMSCs. Further
studies with CD44 have shown that overexpression of CD44 on 8226 cells sensitizes
these cells to HM-27, implicating CD44 as another key protein in the complex with more
studies to be done on CD147 and CD138. It would be interesting to speculate that HYD1
and HM-27 disrupt a complex that contains these proteins that have been shown to be of
vital importance to CAM-DR and metastasis in MM and cancer in general. However
HYD1 and HM-27 could be interacting with each surface protein individually and is not
disrupting a specific complex. Future studies are aimed at determining the primary
binding targets for HYD1 and HM-27 and if direct binding to the target or disruption of a
binding complex induces cell death in MM cells.
We were able to show that expression of α4 integrin in primary patient specimens
correlated with sensitivity towards HYD1 induced cell death ex-vivo, a finding that
correlated well with our cell line observations. We propose that to ensure adequate
designs of trials it is essential to define biomarkers of response using patient specimens in
early phases of drug development, as response markers can take time to validate and
often lag behind the design of early clinical trials[185]. Additionally, our studies indicate
that a larger study determining the prognostic value of VLA-4 integrin is warranted in
multiple myeloma. In the drug resistant cell line, we observed a predominant reduction
in the cleavage of α4 integrin compared to the mature form. Interestingly, α4 integrin is
the only integrin that has been shown to exist in a cleaved and mature form on the plasma
membrane. While there is no definitive answer as to why the α4 integrin is cleaved,
previous studies comparing the cleaved form and mature form have showed that as T
cells are activated they shift expression from the mature form to the cleaved form [186].
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However, functional studies have shown that there is no difference in integrin mediated
adhesion to FN when the two isoforms are compared in chronic myelogenous leukemia
cells [92]. It is intriguing to speculate whether the cleaved fragment of α4 integrin is
required for HYD1 induced cell death and whether the cleaved form has any significance
with respect to disease progression in multiple myeloma.
Recent data demonstrate that targeting α4 integrin in a syngeneic mouse 5TGM1
model via monoclonal antibody treatment reduced the tumor burden in the bone marrow,
spleen and liver[187]. Moreover, the VCAM-1/VLA-4 axis increases MIP-1 alpha and
beta levels and increases the ability of myeloma cells to support osteoclastogenesis[188].
Based on these findings, it will be important to determine whether HYD1 inhibits the
ability of myeloma cells to disrupt bone homeostasis by either inhibiting the activation of
osteoclasts or disrupting the ability of myeloma cells to inhibit the differentiation of
osteoblasts[189-191]. Another strategy for targeting integrins is to inhibit pathways
required for inside-out activation of VLA-4 integrins. Thus VLA-4 can be modulated by
regulating the affinity for ligand as well as clustering or avidity of the integrin
heterodimer[192, 193]. A potential strategy could include targeting Rap1, which is
known to be required for inside out activation of VLA-4[194]. Another approach is
inhibition of CXCR4, where recently, Azab et al. showed that AMD3100 inhibits
adhesion of myeloma cells to stroma and sensitized myeloma cells to chemotherapy in
co-culture models of drug resistance[175]. However, HYD1 is unique to our knowledge,
as in addition to blocking cell adhesion, HYD1 induces necrotic cell death directly in the
myeloma cell, a finding that was not observed with α4 blocking antibody or RGD
containing peptides (data not shown).
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HYD1 induced necrotic cell death was characterized by increased mitochondrial
dysfunction and an increase in ROS. In order to determine pathways that may lead to
increased mitochondrial dysfunction, we analyzed the gene expression profiling data for
changes in expression between H929-60 and H929 cells. One pathway that was
determined to be significant changed using GeneGO software was the intracellular Ca2+
signaling pathway, specifically the release of Ca2+ from ER stores. Guanine nucleotidebinding protein G(q) subunit alpha (GNAQ) is the G protein subunit responsible for the
activation of plc-β and was decreased by 2.5 fold in H929-60 cells. Plc-β is responsible
for the cleavage of PIP2 into DAG and ip3 and was decreased by 2 fold in H929-60 cells.
The ip3 receptor is located on the ER membrane and when bound by ip3 releases Ca2+
from ER stores. There are 3 isoforms of the ip3r but only the 3rd isoform was shown to be
expressed in H929 cells with a 1.9 fold decrease in expression in H929-60 cells.
Previous studies have shown that when Ca2+ is released into the cytosol via release from
ER stores, or when extracellular Ca2+ crosses the plasma membrane, cell death can be
initiated due to mitochondrial Ca2+ overload. Decreased levels of HYD1 and HM-27
induced Ca2+ oscillations in H929-60 cells were observed when compared to H929 cells.
However when these oscillations were inhibited by U73122, there was an increase in
HM-27 induced cell death instead of a decrease in cell death. These data suggest that the
release of Ca2+ after HYD1 and HM-27 treatment contribute to cell survival instead of
cell death. In addition to studies showing that increases in intracellular Ca2+ can cause
mitochondrial overload and increases in ROS, other studies have shown that superoxides
can enhance ip3 induced Ca2+ release from the ER [195]. Preliminary data from our lab
also showed that preincubation with NAC was able to inhibit HYD1 induced Ca2+
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oscillations in H929 and 8226 cells suggesting that an increase in ROS caused the
release of Ca2+ from ER stores after HYD1 treatment. More studies are needed to
determine the association between mitochondrial dysfunction, increases in ROS and Ca2+
release from the ER after treatment with HYD1.
Our data shows that HM-27 is more efficient at eliciting a Ca2+ response in MM
cells when compared to HYD1. On closer examination of the Ca2+ response after
treatment with HM-27, there appears that there could be a biphasic response. It is known
that depleting Ca2+ from ER stores can cause the influx of Ca2+ from the extracellular
compartment via store operated channels. A Ca2+ sensor that spans the ER membrane,
STIM1, is able to detect when ER stores of Ca2+ are depleted. When this happens,
STIM1 interacts with ORAI1 on store operated channels which causes influx of Ca2+ into
the cell. The STIM1/ORAI1 pathway supports the data that there appears to be an initial
smaller Ca2+ response after treatment with HM-27 with a greater response occurring later.
However, depleting extracellular levels of Ca2+ did not decrease the increases in Ca2+
seen after treatment with HM-27 while blocking release of Ca2+ from ER stores did
decrease HM-27 induced Ca2+ levels, indicating that the Ca2+ response seen is through
release of ER stores. It could be argued that the initial increase in Ca2+ is a result of
influx from plasma membrane channels and the subsequent increase in Ca2+ occurs
because of release from ER stores. Pretreatment with U73122 decreased the levels of
intracellular Ca2+ seen after HM-27 treatment to around the levels that are seen during the
primary Ca2+ response after HM-27 treatment. Removing extracellular Ca2+ did not
decrease the overall levels of Ca2+ seen after HM-27 treatment but removing extracellular
Ca2+ and pretreating with U73122 completely blocked the Ca2+ response. Subsequent
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studies are needed to determine the exact mechanism of Ca2+ response after HM-27
treatment.
If increases in intracellular Ca2+ are not causing mitochondrial overload and
necrotic cell death, the next question becomes what is causing these events. Recent
evidence is suggests that necrosis is not just an accidental form of cell death but instead
can be regulated like apoptosis. One such form of regulated necrosis has been termed
necroptosis. Necroptosis has been shown to be activated by ligation of cell death
receptors such as FAS, TNFR and TRAILR. Upon binding of ligands, these receptors
recruit several death domain-containing proteins such as RIP1, RIP3, and caspase 8
[134]. If caspase 8 is not inhibited, caspase 8 cleaves RIP1 and RIP3 and induces caspase
dependent apoptosis. If caspase 8 is inhibited, RIP1 and RIP3 become phosphorylated
and induce necroptosis [135]. Phosphorylated RIP1 causes PARP activation, ATP
depletion, activation of ROS and an increase in intracellular calcium, all considered to be
hallmarks of necrosis. Data generated in our lab showed that inhibiting RIP1 with
necrostatin was able to partially block HM-27 induced cell death, indicating that HM-27
induced cell death may result from necroptosis. One way in which RIP1 causes
mitochondrial dysfunction is through translocation of the mitochondrial fissure protein
DRP1 from the actin cytoskeleton to the mitochondria [196]. Previous studies have also
shown that ligation of the membrane protein CD47, or integrin associated protein, caused
translocation of DRP1 from the cytoskeleton to the mitochondria and caused subsequent
necrotic cell death in B-cell leukemia [197]. It would be intriguing to examine why
HYD1 and HM-27 are causing necrotic cell death in MM cells by either associating with
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death cell receptors on the plasma membrane or by causing translocation of DRP1 from
the cytoskeleton to the mitochondria.
The studies in C57BL/KaLwRijHsd mice show that HM-27 has activity in an in
vivo model and combination treatment of bortezomib and HM-27 seemed to increase
mouse survival while combination treatment with chloroquine and HM-27 did not. The
results with chloroquine and HM-27 were surprising as pretreatment with chloroquine
was shown to potentiate HM-27 induced cell death in vitro and ex vivo. One issue could
be the treatment schedule in mice. As chloroquine has an extremely long half life in in
vivo systems, we decreased the amount of times the mice were treated from 9 days to 3
days. Maybe there would be increased survival after combination treatment if the amount
of treatments were increased to 9. Interestingly, it was also shown that chloroquine had
activity as a single agent. This result is consistent with previous reports that chloroquine
has activity in breast cancer and colon cancer mouse models [198, 199]. Previous data
from our lab has shown that HYD1 potentiated melphalan activity in the SCID-hu model.
Since selection of resistance to melphalan in MM cells results in cells that express higher
levels of α4 integrin, it would be interesting to see if there is increased survival when
these agents are combined in the 5TGM1 mouse model.
Based on the data generated, it is interesting to speculate how HYD1 and HM-27
are inducing cell death in MM myeloma cells. CD44 and VLA-4 have been shown to
localize together on the plasma membrane and have both been shown to mediate cell
adhesion to the ECM protein FN. Adhesion to FN by integrins promotes both the
formation and growth of focal adhesions. One kinase that gets recruited to the focal
adhesion and activates downstream pathways, such as the AKT and ERK pathways, is
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FAK/pyk2. In addition to activating these pathways, FAK/pyk2 has also been shown to
interact with proteins and inhibit death signals when cells are adhered to ecm proteins.
FAK has been shown to interact with the death domain of RIP1, therefore inhibiting the
formation of the death complex and RIP1 mediated cell death [200]. Src has also been
shown to interact with FAK and phosphorylate procaspase-8 on procaspase-8’s Tyr380
residue, resulting in a loss of caspase-8 proapoptotic function [201, 202]. As shown in
figure 40, HYD1/HM-27 could function to mimic a region of FN that binds to CD44. By
mimicking FN and binding to CD44 but not VLA-4, the peptides are causing
disappropriate downstream signaling. Incubation with HYD1/HM-27 has been shown to
cause transient activation of pyk2 and ERK, indicating that HYD1/HM-27 is causing the
formation of focal adhesions and subsequent downstream signaling. However, since
HM-27 is not binding to VLA-4 or other proteins that mediate adhesion to FN,
FAK/pyk2 does not associate with RIP1 and inhibit RIP1’s ability to cause cell death.
However, HYD1/HM-27 binding to CD44 is still causing Src mediated phosphorylation
of procaspase-8 and inhibiting apoptosis induced by caspase-8. This disassociation
would cause RIP1 to generate a death complex resulting in cell death induced by necrosis
and cell survival signals including release of Ca2+ from the ER and induction of
autophagy. One way to test this hypothesis would be to do immunoprecipitation assays
in the presence or absence of FN and compare to immunoprecipitation assays in the
presence and absence of HM-27 to determine if RIP1 associates with pyk2 in the
presence of FN and if this association is disturbed upon treatment with HM-27.
Historically, drug development has focused on aberrations in signaling intrinsic to
the tumor cells using unicellular models. However, it has been argued that tumors evolve
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in the context of the microenvironment, and thus it is feasible that some phenotypes
observed in tumors such as drug resistance and metastasis will only be expressed in the
context of cues derived from the microenvironment [174, 203-205]. In summary, our
data continue to support the premise that targeting survival signals that occur between
tumor cells and the microenvironment is an attractive strategy for increasing the
therapeutic potential of combination regimens and may lead to better clinical
management of cancers such as multiple myeloma considered to be intrinsically resistant
to standard therapy with no currently available curative therapies.
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Figure 40: Proposed mechanism of HM-27 induced cell death. HYD1/HM-27
functions by binding to CD44 and leading to disappropriate signaling. One way that
HYD1/HM-27 could be causing inappropriate signaling is by causing a disassociation of
RIP1 from FAK which enables RIP1 to form a death complex. Formation of the death
complex results in cell death induced by necrosis and cell survival signals including the
release of Ca2+ from the ER and induction of autophagy.
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